Table 2: Historical MIPS Quality Measure Benchmark Results; created using PY2018 data and PY2020 Eligibility Rules,,,,,,,,,,,,,,,,,
Measure_Name,Measure_ID,Collection_Type,Measure_Type,Benchmark,Standard_Deviation,Average,Decile_3,Decile_4,Decile_5,Decile_6,Decile_7,Decile_8,Decile_9,Decile_10,Topped_Out,Seven_Point_Cap,High_Priority
"Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients","102","eCQM","Process","Y","","","71.43 - 91.69","91.7 - 97.11","97.12 - 99.99","--","--","--","--","100.0","No","","Y"
"Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery","191","eCQM","Outcome","Y","","","0.31 - 89.63","89.64 - 94.11","94.12 - 96.14","96.15 - 97.45","97.46 - 98.4","98.41 - 99.08","99.09 - 99.99","100.0","No","","Y"
"""Rate of Carotid Endarterectomy (CEA) for Asymptomatic Patients, without Major Complications (Discharged to Home by Post-Operative Day #2)""","260","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Inflammatory Bowel Disease (IBD): Assessment of Hepatitis B Virus (HBV) Status Before Initiating Anti-TNF (Tumor Necrosis Factor) Therapy","275","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Dementia: Education and Support of Caregivers for Patients with Dementia","288","QCDR Measure","Process","Y","","","0.21 - 44.37","44.38 - 67.95","67.96 - 84.97","84.98 - 94.77","94.78 - 97.62","97.63 - 99.99","--","100.0","No","","Y"
"Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery","303","","patientReportedOutcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Chlamydia Screening for Women","310","eCQM","Process","Y","","","0.1 - 19.99","20.0 - 26.66","26.67 - 32.07","32.08 - 37.65","37.66 - 42.46","42.47 - 47.5","47.51 - 56.06",">= 56.07","No","","N"
"Follow-Up After Hospitalization for Mental Illness (FUH)","391","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Documentation of Signed Opioid Treatment Agreement","412","QCDR Measure","Process","Y","","","0.09 - 31.34","31.35 - 68.78","68.79 - 95.0","95.01 - 99.61","99.62 - 99.99","--","--","100.0","No","","Y"
"Tympanostomy Tubes: Resolution of Otitis Media with Effusion in Adults and Children","AAO36","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Use of Low Dose CT Studies for Adults with Suspicion of Urolithiasis or Nephrolithiasis","ACRAD39","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Hip Arthroplasty: Venous Thromboembolic and Cardiovascular Risk Evaluation","AJRR4","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Coronary Artery Bypass Graft (CABG): Prolonged Intubation – Inverse Measure","AQI18","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Non-Muscle Invasive Bladder Cancer: Early Surveillance Cystoscopy for Non-Muscle Invasive Bladder Cancer","AQUA18","QCDR Measure","Process","Y","","","10.0 - 26.38","26.39 - 28.12","28.13 - 28.37","28.38 - 29.36","29.37 - 33.32","33.33 - 45.31","45.32 - 58.53",">= 58.54","No","","N"
"Post operative hypocalcemia after thyroidectomy surgery","CESQIP1","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Functional Status Change for Patients Post Stroke: Upper Body","FOTO3","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Diabetic Macular Edema - Loss of Visual Acuity","IRIS13","QCDR Measure","Outcome","Y","","","50.0 - 79.48","79.49 - 86.0","86.01 - 87.54","87.55 - 89.07","89.08 - 90.39","90.4 - 92.75","92.76 - 95.46",">= 95.47","No","","Y"
"Avoidance of Routine Antibiotic Use in Patients Before or After Intravitreal Injections","IRIS26","","Efficiency","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Pain Interference Response utilizing PROMIS","MBHR3","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Oncology: Combination chemotherapy recommended or received within 4 months of diagnosis by women under 70 with AJCC stage T1cN0M0 to Stage 1B-III ER/PR negative breast cancer","PIMSH3","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Adult Major Depressive Disorder (MDD): Suicide Risk Assessment","107","eCQM","Process","Y","","","0.01 - 2.03","2.04 - 4.59","4.6 - 10.18","10.19 - 20.78","20.79 - 36.87","36.88 - 56.24","56.25 - 71.66",">= 71.67","No","","N"
"Percentage of Patients Who Died from Cancer Receiving Chemotherapy in the Last 14 Days of Life (lower score – better)","453","QCDR Measure","Process","Y","","","23.08 - 18.57","18.56 - 15.97","15.96 - 14.15","14.14 - 11.64","11.63 - 10.01","10.0 - 8.58","8.57 - 6.19","<= 6.18","No","","Y"
"Continuity of Pharmacotherapy for Opioid Use Disorder (OUD)","468","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Ventral Hernia Repair: Pain and Functional Status Assessment","AHSQC10","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Acute Anterior Uveitis: Post-treatment Grade 0 anterior chamber cells","IRIS17","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Exudative Age-Related Macular Degeneration: Loss of Visual Acuity","IRIS45","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Screening and monitoring for psychosocial problems among children and youth","MBHR5","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Notification to the ordering provider requesting myoglobin or CK-MB in the diagnosis of suspected acute myocardial infarction (AMI)","NPQR1","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Notification to the provider ordering repeat C. difficile stool toxin testing within seven days","NPQR17","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Improved Access Site Bleeding","RCOIR7","QCDR Measure","Outcome","Y","","","57.66 - 74.59","74.6 - 82.94","82.95 - 84.0","84.01 - 86.0","86.01 - 90.04","90.05 - 92.05","92.06 - 93.61",">= 93.62","No","","Y"
"Prolonged Length of Stay Following Coronary Artery Bypass Grafting","STS1","QCDR Measure","Outcome","Y","","","8.47 - 5.8","5.79 - 5.37","5.36 - 5.07","5.06 - 4.01","4.0 - 2.79","2.78 - 2.45","2.44 - 2.21","<= 2.2","No","","Y"
"Patient Centered Surgical Risk Assessment and Communication for Cardiac Surgery","STS7","QCDR Measure","Process","Y","","","0.76 - 24.03","24.04 - 42.85","42.86 - 54.97","54.98 - 66.87","66.88 - 73.32","73.33 - 85.36","85.37 - 95.19",">= 95.2","No","","Y"
"Ankylosing Spondylitis: Controlled Disease","UREQA1","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Referral for Otologic Evaluation for Patients with Acute or Chronic Dizziness","261","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Adult Sinusitis: Antibiotic Prescribed for Acute Viral Sinusitis (Overuse)","331","QCDR Measure","Process","Y","","","87.88 - 76.2","76.19 - 62.59","62.58 - 50.85","50.84 - 37.85","37.84 - 25.78","25.77 - 15.15","15.14 - 5.67","<= 5.66","No","","Y"
"Amyotrophic Lateral Sclerosis (ALS) Patient Care Preferences","386","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Appropriate Follow-up Imaging for Incidental Abdominal Lesions","405","QCDR Measure","Process","Y","","","0.03 - 1.12","1.13 - 1.68","1.69 - 2.6","2.61 - 3.69","3.7 - 5.54","5.55 - 10.41","10.42 - 15.15",">= 15.16","No","","Y"
"Appropriate Follow-up Imaging for Incidental Abdominal Lesions","405","Medicare Part B Claims","Process","Y","","","0.05 - 3.22","3.23 - 4.54","4.55 - 6.66","6.67 - 9.51","9.52 - 11.99","12.0 - 14.28","14.29 - 21.73",">= 21.74","No","","Y"
"Back Pain After Lumbar Fusion","460","","patientReportedOutcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Otitis Media with Effusion (OME): Avoidance of Inappropriate Use of Medications","AAO31","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Adult OSA: Screening for Adult OSA by Primary Care Physicians","AASM3","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Measuring the Value-Functions of Primary Care: Provider Level Continuity Measure","ABFM9","","Efficiency","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Closing the Mohs Surgery Referral Loop: Transmission of Surgical Report","ACMS2","QCDR Measure","Process","Y","","","3.7 - 89.11","89.12 - 92.02","92.03 - 96.38","96.39 - 97.58","97.59 - 98.32","98.33 - 99.51","99.52 - 99.84",">= 99.85","No","","Y"
"Interpretation of CT Pulmonary Angiography (CTPA) for Pulmonary Embolism","ACRAD37","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Obstructive Sleep Apnea: Patient Education","AQI62","QCDR Measure","Process","Y","","","0.02 - 77.57","77.58 - 88.21","88.22 - 94.58","94.59 - 97.59","97.6 - 99.56","99.57 - 99.83","99.84 - 99.99","100.0","No","","N"
"Stones: Urinalysis Performed Before Surgical Stone Procedures","AQUA15","QCDR Measure","Process","Y","","","2.44 - 47.83","47.84 - 53.18","53.19 - 63.14","63.15 - 69.66","69.67 - 74.65","74.66 - 76.97","76.98 - 84.09",">= 84.1","No","","Y"
"""Cancer Protocol and Turnaround Time for Gynecologic and Genitourinary Carcinomas: Carcinoma of the Endometrium, Prostate, and Renal Tubular Origin""","CAP37","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Appropriate Use of hyperbaric oxygen therapy for patients with diabetic foot ulcers","CDR8","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Avoid Head CT for Patients with Uncomplicated Syncope","ECPR39","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Critical Care Transfer of Care – Use of Verbal Checklist or Protocol","HCPR22","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Surgery for Acquired Involutional Ptosis: Patients with an improvement of marginal reflex distance (MRD)","IRIS5","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"CHANGE IN PATIENT REPORTED QUALITY OF LIFE FOLLOWING INTERSPINOUS INDIRECT DECOMPRESSION (SPACER)","NIPM25","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Time interval: critical value reporting for cerebrospinal fluid - white blood cell (CSF - WBC)","NPQR5","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Assessment for and management of immune-related adverse events during cancer treatment with checkpoint inhibitors (ICPi)","ONSQIR23","","Intermediate Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Oncology: Hepatitis B serology testing and prophylactic treatment prior to receiving anti-CD20 targeting drugs","PIMSH10","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"""Measurement-based Care Processes: Baseline Assessment, Monitoring and Treatment Adjustment""","PP8","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Arteriovenous Graft Thrombectomy Success Rate","RPAQIR14","QCDR Measure","Outcome","Y","","","50.49 - 79.42","79.43 - 82.13","82.14 - 85.55","85.56 - 86.97","86.98 - 89.03","89.04 - 91.85","91.86 - 93.83",">= 93.84","No","","Y"
"Percent of patients meeting SCB thresholds for pain-related disability (ODI/NDI)","SPINETRACK6","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Hematology: Multiple Myeloma: Treatment with Bisphosphonates","69","QCDR Measure","Process","Y","","","5.71 - 35.28","35.29 - 49.99","50.0 - 63.63","63.64 - 75.85","75.86 - 79.48","79.49 - 84.99","85.0 - 92.3",">= 92.31","No","","N"
"Melanoma: Continuity of Care – Recall System","137","QCDR Measure","Structure","Y","","","0.14 - 95.21","95.22 - 98.89","98.9 - 99.99","--","--","--","--","100.0","No","","Y"
"Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents","239","eCQM","Process","Y","","","0.02 - 27.52","27.53 - 30.5","30.51 - 32.18","32.19 - 33.32","33.33 - 34.61","34.62 - 38.64","38.65 - 47.92",">= 47.93","No","","N"
"Sleep Apnea: Assessment of Adherence to Positive Airway Pressure Therapy","279","QCDR Measure","Process","Y","","","0.23 - 86.58","86.59 - 95.64","95.65 - 98.63","98.64 - 99.99","--","--","--","100.0","No","","N"
"Pain Brought Under Control Within 48 Hours","342","QCDR Measure","Outcome","Y","","","32.56 - 99.99","--","--","--","--","--","--","100.0","No","","Y"
"Functional Status Assessment for Total Hip Replacement","376","eCQM","Process","Y","","","0.23 - 4.72","4.73 - 8.32","8.33 - 11.53","11.54 - 15.82","15.83 - 19.74","19.75 - 33.32","33.33 - 53.56",">= 53.57","No","","Y"
"Functional Status Assessments for Congestive Heart Failure","377","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Osteoporosis Management in Women Who Had a Fracture","418","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Dermatitis – Improvement in Patient-Reported Itch Severity","AAD10","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Migraine Preventive Therapy Management","AAN30","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Age-related Hearing Loss: Audiometric Evaluation","AAO16","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Quality of Life for Patients with Neurotology Disorders","AAO29","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"""Mismatch Repair (MMR) or Microsatellite Instability (MSI) Biomarker Testing Status in Colorectal Carcinoma, Endometrial, Gastroesophageal, or Small Bowel Carcinoma""","CAP33","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Appropriate Treatment of Psychosis and Agitation in the Emergency Department","ECPR52","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Physician’s Orders for Life-Sustaining Treatment (POLST) Form","HCPR16","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"""Myocardial Perfusion Imaging (MPI) Studies, Transthoracic Echo (TTE), or Stress Echocardiography Imaging Studies - Adequate Reporting for Appropriate Interventions""","IGR16","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"""Failure to Progress (FTP): Proportion of patients failing to achieve a Minimal Clinically Important Difference (MCID) in improvement in pain score, measured via the Numeric Pain Rating Scale (NPRS), in rehabilitation patients with hip, leg or ankle (lower extremity except knee) injury.""","IROMS14","QCDR Measure","Outcome","Y","","","54.44 - 52.39","52.38 - 50.57","50.56 - 49.71","49.7 - 48.29","48.28 - 47.12","47.11 - 45.78","45.77 - 44.58","<= 44.57","No","","Y"
"Posttraumatic Stress Disorder (PTSD) Outcome Assessment for Adults and Children","MBHR7","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Percutaneous Arteriovenous Fistula for Dialysis - Clinical Success Rate","RCOIR13","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Leg Pain After Lumbar Fusion","473","","patientReportedOutcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Documentation of Clinical Response to Allergen Immunotherapy within One Year","AAAAI6","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Appropriate Emergency Department Utilization of Lumbar Spine Imaging for Atraumatic Low Back Pain","ACEP52","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Patient-Reported Pain and/or Function Improvement after APM Surgery","CCOME6","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Functional Status Change for Patients with Vestibular Dysfunction","HM7","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Appropriate diagnosis verification and severity grading for valve disease through transthoracic echocardiography (TTE) quantitative parameters.","IGR12","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Use of Anxiety Severity Measure","MBHR1","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Anxiety Response at 6-months","MBHR2","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Social Role Functioning Outcome utilizing PROMIS","MBHR4","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Concurrent Chemo radiation for Patients with a Diagnosis of Stage IIIB NSCLC","QOPI23","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Peritoneal Dialysis Catheter Success Rate","RPAQIR16","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Oncology: Medical and Radiation – Pain Intensity Quantified","143","eCQM","Process","Y","","","0.44 - 76.31","76.32 - 89.58","89.59 - 94.1","94.11 - 96.56","96.57 - 97.8","97.81 - 98.76","98.77 - 99.75",">= 99.76","No","","Y"
"Rate of Endovascular Aneurysm Repair (EVAR) of Small or Moderate Non-Ruptured Infrarenal Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #2)","259","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Appropriate Assessment of Retrievable Inferior Vena Cava (IVC) Filters for Removal","421","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Functional Status After Lumbar Discectomy/Laminectomy","471","","patientReportedOutcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Medication Prescribed For Acute Migraine Attack","AAN5","QCDR Measure","Process","Y","","","16.67 - 50.43","50.44 - 54.85","54.86 - 58.62","58.63 - 63.17","63.18 - 69.29","69.3 - 73.35","73.36 - 79.85",">= 79.86","No","","N"
"Pediatric OSA: Objective Assessment of OSA Signs and Symptoms in Children with Complex Medical Conditions","AASM2","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"COPD: Steroids for no more than 5 days in COPD Exacerbation","ACQR3","QCDR Measure","Efficiency and Cost/Resource Use","Y","","","77.03 - 91.1","91.11 - 92.54","92.55 - 94.4","94.41 - 95.64","95.65 - 96.69","96.7 - 97.36","97.37 - 98.3",">= 98.31","No","","Y"
"Report Turnaround Time: Ultrasound (Excluding Breast US)","ACRAD16","QCDR Measure","Outcome","Y","","","11.77 - 8.08","8.07 - 6.45","6.44 - 4.93","4.92 - 4.12","4.11 - 3.38","3.37 - 2.39","2.38 - 1.77","<= 1.76","No","","Y"
"Report Turnaround Time: MRI","ACRAD17","QCDR Measure","Outcome","Y","","","20.92 - 16.21","16.2 - 12.08","12.07 - 9.62","9.61 - 8.14","8.13 - 6.18","6.17 - 5.04","5.03 - 3.78","<= 3.77","No","","Y"
"Hip/Knee Replacement: Postoperative Ambulation","AJRR7","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Perioperative Anemia Management","AQI72","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Review of Pain Status Assessment for Patients with Osteoarthritis","FORCE21","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Appropriate Evaluation of Left Ventricular Structure and Systolic Function with Transthoracic Echocardiography (TTE) to Guide Heart Failure and Cardiomyopathy Management","IGR14","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Myocardial Perfusion Imaging (MPI) or Stress Echocardiography imaging studies - Improving Image Quality","IGR18","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Improvement of Macular Edema in Patients with Uveitis","IRIS35","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Improved visual acuity after epiretinal membrane treatment within 120 days","IRIS41","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"""Failure to Progress (FTP): Proportion of patients failing to achieve a Minimal Clinically Important Difference (MCID) in improvement in pain score, measured via the Numeric Pain Rating Scale (NPRS), in rehabilitation patients with knee injury pain.""","IROMS12","QCDR Measure","Outcome","Y","","","48.78 - 46.39","46.38 - 44.45","44.44 - 43.76","43.75 - 41.58","41.57 - 39.75","39.74 - 38.11","38.1 - 37.39","<= 37.38","No","","Y"
"Kidney Stones: SWL in patients with largest renal stone > 2 cm or lower pole stone > 1 cm","MUSIC15","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Time interval: critical value reporting for chemistry","NPQR4","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"IVC Filter Management Confirmation","QMM16","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation","12","eCQM","Process","Y","","","0.38 - 83.8","83.81 - 88.82","88.83 - 92.41","92.42 - 95.16","95.17 - 96.98","96.99 - 98.32","98.33 - 99.27",">= 99.28","No","","N"
"Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation","12","Medicare Part B Claims","Process","Y","","","5.45 - 99.99","--","--","--","--","--","--","100.0","No","","N"
"Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation","12","QCDR Measure","Process","Y","","","3.45 - 96.5","96.51 - 98.52","98.53 - 99.43","99.44 - 99.99","--","--","--","100.0","No","","N"
"Prevention of Central Venous Catheter (CVC) - Related Bloodstream Infections","76","QCDR Measure","Process","Y","","","7.94 - 97.02","97.03 - 99.35","99.36 - 99.99","--","--","--","--","100.0","No","","Y"
"Prevention of Central Venous Catheter (CVC) - Related Bloodstream Infections","76","Medicare Part B Claims","Process","Y","","","0.79 - 99.99","--","--","--","--","--","--","100.0","No","","Y"
"Diabetes: Eye Exam","117","eCQM","Process","Y","","","0.06 - 13.74","13.75 - 23.42","23.43 - 35.91","35.92 - 55.41","55.42 - 87.38","87.39 - 96.88","96.89 - 99.27",">= 99.28","No","","N"
"Diabetes: Eye Exam","117","Medicare Part B Claims","Process","Y","","","0.75 - 98.27","98.28 - 99.99","--","--","--","--","--","100.0","No","","N"
"Rheumatoid Arthritis (RA): Glucocorticoid Management","180","QCDR Measure","Process","Y","","","0.26 - 98.44","98.45 - 99.77","99.78 - 99.99","--","--","--","--","100.0","No","","N"
"Elder Maltreatment Screen and Follow-Up Plan","181","Medicare Part B Claims","Process","Y","","","0.08 - 97.04","97.05 - 99.83","99.84 - 99.99","--","--","--","--","100.0","No","","Y"
"Elder Maltreatment Screen and Follow-Up Plan","181","QCDR Measure","Process","Y","","","2.62 - 63.59","63.6 - 78.65","78.66 - 90.73","90.74 - 96.01","96.02 - 99.56","99.57 - 99.99","--","100.0","No","","Y"
"Use of High-Risk Medications in Older Adults","238","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Psoriasis: Screening for Psoriatic Arthritis","AAD7","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Follow-Up Care Coordination Documented in Discharge Summary","ACEP56","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Functional Status Change for Patients With Upper-limb Functional Status Deficit","HM4","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Acute Anterior Uveitis: Post-treatment visual acuity","IRIS51","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Complications After Cataract Surgery","IRIS54","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Sleep Quality Assessment and Sleep Response at 3-months","MBHR6","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"""Functional Status Change for Patients with Lower Leg, Foot or Ankle Impairments""","219","QCDR Measure","patientReportedOutcome","Y","","","67.86 - 93.17","93.18 - 94.89","94.9 - 96.35","96.36 - 97.75","97.76 - 98.98","98.99 - 99.99","--","100.0","No","","Y"
"Biopsy Follow-Up","265","QCDR Measure","Process","Y","","","0.06 - 76.98","76.99 - 95.3","95.31 - 99.03","99.04 - 99.99","--","--","--","100.0","No","","Y"
"Dementia: Cognitive Assessment","281","eCQM","Process","Y","","","0.04 - 7.68","7.69 - 13.42","13.43 - 21.73","21.74 - 31.71","31.72 - 44.43","44.44 - 59.45","59.46 - 73.73",">= 73.74","No","","N"
"Cataracts: Patient Satisfaction within 90 Days Following Cataract Surgery","304","","Patient Engagement/Experience","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Lung Cancer Reporting (Resection Specimens)","396","Medicare Part B Claims","Process","Y","","","95.24 - 99.99","--","--","--","--","--","--","100.0","No","","Y"
"Lung Cancer Reporting (Resection Specimens)","396","QCDR Measure","Process","Y","","","84.62 - 99.99","--","--","--","--","--","--","100.0","No","","Y"
"Anesthesiology Smoking Abstinence","404","QCDR Measure","Intermediate Outcome","Y","","","1.1 - 52.12","52.13 - 61.34","61.35 - 67.56","67.57 - 72.47","72.48 - 78.42","78.43 - 83.57","83.58 - 90.54",">= 90.55","No","","Y"
"Skin Cancer: Biopsy Reporting Time – Pathologist to Clinician","440","QCDR Measure","Process","Y","","","2.54 - 98.28","98.29 - 99.69","99.7 - 99.99","--","--","--","--","100.0","No","","Y"
"Preventive Treatment Prescribed for Cluster Headache","AAN32","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Appropriate Use of Imaging for Recurrent Renal Colic","ACEP53","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Report Turnaround Time: Radiography","ACRAD15","QCDR Measure","Outcome","Y","","","9.52 - 6.05","6.04 - 4.58","4.57 - 3.55","3.54 - 2.57","2.56 - 1.94","1.93 - 1.48","1.47 - 1.16","<= 1.15","No","","Y"
"Patient-Reported Experience with Anesthesia","AQI48","QCDR Measure","Outcome","Y","","","75.0 - 90.17","90.18 - 91.05","91.06 - 91.9","91.91 - 92.58","92.59 - 93.09","93.1 - 94.59","94.6 - 95.51",">= 95.52","No","","Y"
"Patient Satisfaction with Rhinoplasty Procedure","ASPS17","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Visits to the ER or Urgent Care Following Reconstruction After Skin Cancer Resection","ASPS24","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Extent of Osteoarthritis Observed in Arthroscopic Partial Meniscectomy","CCOME5","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Symptom Improvement in adults with ADHD","MBHR10","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"PCR Test with MR2 or greater result (BCR-ABL1 transcript level <= 1% [IS]) for patients receiving TKI for at least 6 months for Chronic Myelogenous Leukemia","ONSQIR22","","Intermediate Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Cardiac Tamponade and/or Pericardiocentesis Following Atrial Fibrillation Ablation","392","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Functional Status After Primary Total Knee Replacement","470","","patientReportedOutcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Diabetic Foot Ulcer (DFU) Healing or Closure","CDR2","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Appropriate management of anticoagulation in the peri-procedural period rate – EGD","GIQIC10","QCDR Measure","Process","Y","","","2.94 - 68.17","68.18 - 79.82","79.83 - 86.82","86.83 - 91.9","91.91 - 96.06","96.07 - 99.99","--","100.0","No","","Y"
"Clostridium Difficile – Risk Assessment and Plan of Care","HCPR20","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Functional Status Change for Patients With Low Back Functional Status Deficit","HM6","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Adult Surgical Esotropia: Postoperative alignment","IRIS48","QCDR Measure","Outcome","Y","","","1.54 - 2.85","2.86 - 4.41","4.42 - 6.0","6.01 - 7.69","7.7 - 15.6","15.61 - 22.61","22.62 - 31.24",">= 31.25","No","","Y"
"Kidney Stones: ED visit within 30 days of ureteroscopy","MUSIC12","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Prostate Cancer: Urinary continence at 12 months post-radical prostatectomy","MUSIC22","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Renal Mass: Documentation of the RENAL score for patients with small renal mass diagnoses","MUSIC23","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Renal Mass: ED visit or Readmission within 30 days of radical nephrectomy","MUSIC25","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"""Oncology: Utilization of PET, PET/CT, or CT scans for breast cancer stage 0, I, or II at any time during the course of evaluation and treatment""","PIMSH11","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Percent of patients meeting SCB thresholds for leg or arm pain","SPINETRACK5","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Assessment of Nutritionally At-Risk Patients for Malnutrition and Development of Nutrition Recommendations/Interventions by a Registered Dietitian Nutritionist","USWR27","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Appropriate Treatment for Upper Respiratory Infection (URI)","65","eCQM","Process","Y","","","14.94 - 79.88","79.89 - 84.7","84.71 - 88.54","88.55 - 91.97","91.98 - 94.94","94.95 - 97.32","97.33 - 99.43",">= 99.44","No","","Y"
"Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy","147","Medicare Part B Claims","Process","Y","","","3.57 - 71.2","71.21 - 85.18","85.19 - 95.05","95.06 - 97.95","97.96 - 99.99","--","--","100.0","No","","Y"
"Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy","147","QCDR Measure","Process","Y","","","4.12 - 93.32","93.33 - 98.93","98.94 - 99.99","--","--","--","--","100.0","No","","Y"
"Coronary Artery Bypass Graft (CABG): Prolonged Intubation","164","QCDR Measure","Outcome","Y","","","12.2 - 8.81","8.8 - 7.7","7.69 - 6.01","6.0 - 4.68","4.67 - 2.95","2.94 - 2.37","2.36 - 1.07","<= 1.06","No","","Y"
"Colonoscopy Interval for Patients with a History of Adenomatous Polyps – Avoidance of Inappropriate Use","185","QCDR Measure","Process","Y","","","0.17 - 51.54","51.55 - 83.42","83.43 - 91.51","91.52 - 96.28","96.29 - 98.07","98.08 - 99.57","99.58 - 99.99","100.0","No","","Y"
"Sleep Apnea: Severity Assessment at Initial Diagnosis","277","QCDR Measure","Process","Y","","","0.23 - 19.99","20.0 - 42.79","42.8 - 58.22","58.23 - 74.85","74.86 - 93.7","93.71 - 99.99","--","100.0","No","","N"
"Cataract Surgery: Difference Between Planned and Final Refraction","389","QCDR Measure","Outcome","Y","","","0.93 - 30.01","30.02 - 37.88","37.89 - 51.9","51.91 - 68.88","68.89 - 93.34","93.35 - 98.18","98.19 - 99.99","100.0","No","","Y"
"Radiation Consideration for Adult CT: Utilization of Dose Lowering Techniques","436","QCDR Measure","Process","Y","","","0.02 - 98.98","98.99 - 99.81","99.82 - 99.97","99.98 - 99.99","--","--","--","100.0","No","","N"
"Radiation Consideration for Adult CT: Utilization of Dose Lowering Techniques","436","Medicare Part B Claims","Process","Y","","","0.09 - 96.34","96.35 - 98.65","98.66 - 99.52","99.53 - 99.85","99.86 - 99.99","--","--","100.0","No","","N"
"Percentage of Patients Who Died from Cancer Admitted to the Intensive Care Unit (ICU) in the Last 30 Days of Life (lower score – better)","455","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"All-cause Hospital Readmission","458","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Urinary Symptom Score Change 6-12 Months After Diagnosis of Benign Prostatic Hyperplasia","476","","patientReportedOutcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Melanoma: – Appropriate Surgical Margins","AAD12","","Intermediate Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Tympanostomy Tubes: Hearing Test","AAO20","QCDR Measure","Process","Y","","","72.01 - 95.76","95.77 - 97.49","97.5 - 97.8","97.81 - 98.38","98.39 - 98.77","98.78 - 98.9","98.91 - 99.29",">= 99.3","No","","N"
"Pediatric OSA: Objective Assessment of Positive Airway Pressure Therapy Adherence","AASM1","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Coagulation Studies in Patients Presenting with Chest Pain with No Coagulopathy or Bleeding","ACEP21","QCDR Measure","Process","Y","","","19.74 - 14.84","14.83 - 11.0","10.99 - 9.16","9.15 - 6.56","6.55 - 4.82","4.81 - 3.62","3.61 - 2.7","<= 2.69","No","","Y"
"Hepatitis B Safety Screening","ACR10","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Rheumatoid Arthritis Patients with Low Disease Activity or Remission","ACR16","","Intermediate Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Functional Status Changes for Patients with Upper or Lower Extremity Regional Swelling","FOTO4","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Outcomes of Hearing Loss Treatment","HM10","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Use of ASPECTS (Alberta Stroke Program Early CT Score) for non-contrast CT Head performed for suspected acute stroke.","MEDNAX55","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Prostate Cancer: Confirmation Testing in low risk AS eligible patients","MUSIC10","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Notification to the provider ordering repeat blood chemistry panels in clinically stable patients within four days.","NPQR16","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Tunneled Hemodialysis Catheter Success","RCOIR12","QCDR Measure","Outcome","Y","","","18.06 - 60.97","60.98 - 66.98","66.99 - 70.16","70.17 - 76.04","76.05 - 78.3","78.31 - 81.67","81.68 - 84.65",">= 84.66","No","","Y"
"End Stage Renal Disease (ESRD) Initiation of Home Dialysis or Self-Care","RCOIR5","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Use of Ankle Foot Orthotics to improve patient function","REGCLR7","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Radiology: Reminder System for Screening Mammograms","225","Medicare Part B Claims","Structure","Y","","","0.1 - 99.99","--","--","--","--","--","--","100.0","No","","Y"
"Radiology: Reminder System for Screening Mammograms","225","QCDR Measure","Structure","Y","","","0.01 - 99.99","--","--","--","--","--","--","100.0","No","","Y"
"Rate of Open Repair of Small or Moderate Non-Ruptured Infrarenal Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #7)","258","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Adult Primary Rhegmatogenous Retinal Detachment Surgery: Visual Acuity Improvement Within 90 Days of Surgery","385","QCDR Measure","Outcome","Y","","","10.11 - 42.85","42.86 - 47.99","48.0 - 51.05","51.06 - 58.27","58.28 - 66.66","66.67 - 71.42","71.43 - 75.7",">= 75.71","No","","Y"
"Performing Cystoscopy at the Time of Hysterectomy for Pelvic Organ Prolapse to Detect Lower Urinary Tract Injury","422","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Functional Status After Lumbar Fusion","469","","patientReportedOutcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Appropriate Use of DXA Scans in Women Under 65 Years Who Do Not Meet the Risk Factor Profile for Osteoporotic Fracture","472","eCQM","Process","Y","","","--","--","--","--","--","--","--","0.0","No","","Y"
"Asthma: Assessment of Asthma Control – Ambulatory Care Setting","AAAAI2","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Known or Suspected Difficult Airway Mitigation Strategies","ABG42","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Avoidance of Cerebral Hyperthermia for Procedures Involving Cardiopulmonary Bypass","AQI65","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Turnaround Time (TAT) - Biopsies","CAP22","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"""Prostate Cancer Gleason Pattern, Score, and Grade Group""","CAP32","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Patient-Reported Pain and/or Function Improvement after Total Shoulder Arthroplasty","CCOME8","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Outcomes of Treatment of Benign Paroxysmal Positional Vertigo","HM12","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Glaucoma – Intraocular Pressure Reduction","IRIS2","QCDR Measure","Intermediate Outcome","Y","","","0.2 - 75.01","75.02 - 87.35","87.36 - 91.88","91.89 - 93.52","93.53 - 95.25","95.26 - 96.35","96.36 - 97.2",">= 97.21","No","","Y"
"Outcome monitoring of ADHD functional impairment in children and youth","MBHR9","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Prostate Cancer: Active Surveillance/Watchful Waiting for Low Risk Prostate Cancer Patients","MUSIC4","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Rate of communicating results of an amended report with a major discrepancy to the responsible provider","NPQR11","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Oncology: Advance Care Planning in metastatic cancer patients","PIMSH1","QCDR Measure","Patient Engagement/Experience","Y","","","0.07 - 2.16","2.17 - 3.4","3.41 - 5.74","5.75 - 17.58","17.59 - 29.99","30.0 - 41.39","41.4 - 48.81",">= 48.82","No","","Y"
"Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older","48","Medicare Part B Claims","Process","Y","","","0.04 - 74.4","74.41 - 98.0","98.01 - 99.99","--","--","--","--","100.0","No","","N"
"Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older","48","QCDR Measure","Process","Y","","","0.2 - 23.37","23.38 - 38.84","38.85 - 56.05","56.06 - 71.59","71.6 - 80.54","80.55 - 91.85","91.86 - 98.09",">= 98.1","No","","N"
"Initiation and Engagement of Alcohol and Other Drug Dependence Treatment","305","eCQM","Process","Y","","","0.02 - 0.26","0.27 - 0.42","0.43 - 0.6","0.61 - 0.9","0.91 - 1.22","1.23 - 1.79","1.8 - 2.82",">= 2.83","No","","Y"
"Adult Primary Rhegmatogenous Retinal Detachment Surgery: No Return to the Operating Room Within 90 Days of Surgery","384","QCDR Measure","Outcome","Y","","","60.0 - 95.99","96.0 - 99.99","--","--","--","--","--","100.0","No","","Y"
"Ischemic Vascular Disease (IVD) All or None Outcome Measure (Optimal Control)","441","QCDR Measure","Intermediate Outcome","Y","","","0.01 - 14.07","14.08 - 22.62","22.63 - 28.38","28.39 - 36.81","36.82 - 42.85","42.86 - 48.71","48.72 - 55.61",">= 55.62","No","","Y"
"Medication Management for People with Asthma","444","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Appropriate Emergency Department Utilization of CT for Pulmonary Embolism","ACEP22","QCDR Measure","Process","Y","","","10.41 - 21.54","21.55 - 24.47","24.48 - 27.66","27.67 - 32.72","32.73 - 37.21","37.22 - 41.45","41.46 - 45.1",">= 45.11","No","","Y"
"ED Median Time from ED arrival to ED departure for all Pediatric Patients","ACEP51","QCDR Measure","Outcome","Y","","","0.06 - -0.02","-0.03 - -0.11","-0.12 - -0.18","-0.19 - -0.23","-0.24 - -0.27","-0.28 - -0.33","-0.34 - -0.39","<= -0.4","No","","Y"
"Use of a risk stratification tool in patients with CAP","ACQR15","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Report Turnaround Time: PET","ACRAD19","QCDR Measure","Outcome","Y","","","56.55 - 38.46","38.45 - 21.33","21.32 - 14.17","14.16 - 9.86","9.85 - 8.14","8.13 - 6.81","6.8 - 5.09","<= 5.08","No","","Y"
"Shared-decision making for post-operative management of discomfort following Rhinoplasty","ASPS18","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"p16 Immunohistochemistry Reporting for Human Papillomavirus in Patients with Oropharyngeal Squamous Cell Carcinoma (OPSCC)","CAP36","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"qPTH >50% Reduction at End of Procedure","CESQIP9","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Ultrasound Guidance for Peripheral Nerve Block with Patient Experience","EPREOP30","QCDR Measure","Outcome","Y","","","81.82 - 87.67","87.68 - 89.66","89.67 - 90.71","90.72 - 91.37","91.38 - 92.86","92.87 - 93.95","93.96 - 95.51",">= 95.52","No","","Y"
"Refractive Surgery: Patients with a postoperative correction within + or - 0.5 Diopter (D) of the intended correction","IRIS24","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Acquired Involutional Entropion: Normalized lid position after surgical repair","IRIS6","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Screening Coronary Calcium Scoring for Cardiovascular Risk Assessment Including Coronary Artery Calcification Regional Distribution Scoring","MSN13","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Time interval: critical value reporting for toxicology","NPQR6","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Appropriate Follow-up Recommendations for Ovarian-Adnexal Lesions using the Ovarian-Adnexal Reporting and Data System (O-RADS)","QMM17","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Heel Pain Treatment Outcomes for Pediatric Patients","REGCLR4","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care","19","Medicare Part B Claims","Process","Y","","","44.83 - 99.99","--","--","--","--","--","--","100.0","No","","Y"
"Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care","19","eCQM","Process","Y","","","0.04 - 58.07","58.08 - 69.99","70.0 - 78.71","78.72 - 85.19","85.2 - 90.44","90.45 - 94.43","94.44 - 97.45",">= 97.46","No","","Y"
"""Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention – Evaluation of Footwear""","127","QCDR Measure","Process","Y","","","0.06 - 58.56","58.57 - 73.56","73.57 - 84.87","84.88 - 94.34","94.35 - 98.94","98.95 - 99.99","--","100.0","No","","N"
"Falls: Risk Assessment","154","Medicare Part B Claims","Process","Y","","","0.48 - 98.74","98.75 - 99.99","--","--","--","--","--","100.0","No","","Y"
"Falls: Risk Assessment","154","QCDR Measure","Process","Y","","","0.14 - 88.18","88.19 - 96.29","96.3 - 98.86","98.87 - 99.99","--","--","--","100.0","No","","Y"
"Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low-Risk Surgery Patients","322","QCDR Measure","Efficiency and Cost/Resource Use","Y","","","3.61 - 0.34","0.33 - 0.01","--","--","--","--","--","0.0","No","","Y"
"Implantable Cardioverter-Defibrillator (ICD) Complications Rate","348","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Optimizing Patient Exposure to Ionizing Radiation: Appropriateness: Follow-up CT Imaging for Incidentally Detected Pulmonary Nodules According to Recommended Guidelines","364","QCDR Measure","Process","Y","","","21.4 - 95.58","95.59 - 98.24","98.25 - 99.99","--","--","--","--","100.0","No","","Y"
"""Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists""","379","eCQM","Process","Y","","","0.0 - 0.25","0.26 - 0.5","0.51 - 1.08","1.09 - 2.1","2.11 - 3.84","3.85 - 5.22","5.23 - 7.04",">= 7.05","No","","N"
"Hepatitis C: Screening for Hepatocellular Carcinoma (HCC) in Patients with Cirrhosis","401","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Appropriate Treatment for Patients with Stage I (T1c) - III HER2 Positive Breast Cancer","450","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"RAS (KRAS and NRAS) Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Therapy","451","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Quality of Life Outcome for Patients with Neurologic Conditions","AAN22","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Acute Treatment Prescribed for Cluster Headache","AAN31","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Bell's Palsy: Inappropriate Use of Magnetic Resonance Imaging or Computed Tomography Scan (Inverse Measure)","AAO13","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"ED Median Time from ED arrival to ED departure for all Adult Patients","ACEP50","QCDR Measure","Outcome","Y","","","0.13 - 0.01","0.0 - -0.07","-0.08 - -0.13","-0.14 - -0.21","-0.22 - -0.26","-0.27 - -0.29","-0.3 - -0.35","<= -0.36","No","","Y"
"Use of Quantitative Criteria for Oncologic FDG PET Imaging","ACRAD41","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Non-Muscle Invasive Bladder Cancer: Repeat Transurethral Resection of Bladder Tumor (TURBT) for T1 disease","AQUA16","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Biomarker Status to Inform Clinical Management and Treatment Decisions in Patients with Non-small Cell Lung Cancer","CAP34","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Post-operative opioid management following ocular surgery","IRIS52","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Prostate Cancer: Complications within 30 days of radical prostatectomy","MUSIC20","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Improvement or Maintenance of Functioning for Individuals with a Mental Health and/or Substance Use Disorder","PP9","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Appropriate Antiemetic Therapy for High- and Moderate Emetic Risk Antineoplastic Agents","QOPI27","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Unplanned hospital readmission following spinal fusion surgery.","SPINETRACK9","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Pressure Ulcer* (PU) Healing or Closure for ulcers on the torso (body)","USWR25","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Patient Reported Outcome of late effects of radiation symptoms following treatment with Hyperbaric Oxygen Therapy (HBOT)","USWR26","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD)","5","eCQM","Process","Y","","","1.09 - 72.72","72.73 - 77.67","77.68 - 81.81","81.82 - 87.09","87.1 - 93.38","93.39 - 98.19","98.2 - 99.99","100.0","No","","N"
"Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)","23","Medicare Part B Claims","Process","Y","","","0.06 - 99.99","--","--","--","--","--","--","100.0","No","","Y"
"Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)","23","QCDR Measure","Process","Y","","","0.23 - 95.23","95.24 - 99.58","99.59 - 99.99","--","--","--","--","100.0","No","","Y"
"Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery","44","QCDR Measure","Process","Y","","","24.04 - 94.14","94.15 - 96.5","96.51 - 98.56","98.57 - 99.99","--","--","--","100.0","No","","N"
"Preventive Care and Screening: Screening for Depression and Follow-Up Plan","134","eCQM","Process","Y","","","0.01 - 8.22","8.23 - 16.47","16.48 - 26.03","26.04 - 38.66","38.67 - 51.49","51.5 - 65.66","65.67 - 80.31",">= 80.32","No","","N"
"Preventive Care and Screening: Screening for Depression and Follow-Up Plan","134","Medicare Part B Claims","Process","Y","","","0.06 - 95.65","95.66 - 99.62","99.63 - 99.99","--","--","--","--","100.0","No","","N"
"Dementia: Functional Status Assessment","282","QCDR Measure","Process","Y","","","0.12 - 45.74","45.75 - 75.03","75.04 - 92.99","93.0 - 98.9","98.91 - 99.99","--","--","100.0","No","","N"
"Dementia: Safety Concern Screening and Follow-Up for Patients with Dementia","286","QCDR Measure","Process","Y","","","0.12 - 87.19","87.2 - 92.95","92.96 - 97.42","97.43 - 99.99","--","--","--","100.0","No","","Y"
"Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients","320","QCDR Measure","Process","Y","","","1.11 - 84.77","84.78 - 90.23","90.24 - 93.99","94.0 - 96.32","96.33 - 98.02","98.03 - 98.87","98.88 - 99.99","100.0","No","","Y"
"Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients","320","Medicare Part B Claims","Process","Y","","","5.61 - 92.25","92.26 - 97.91","97.92 - 99.99","--","--","--","--","100.0","No","","Y"
"Patient-Centered Surgical Risk Assessment and Communication","358","QCDR Measure","Process","Y","","","0.34 - 33.32","33.33 - 71.67","71.68 - 91.42","91.43 - 98.29","98.3 - 99.99","--","--","100.0","No","","Y"
"Perioperative Temperature Management","424","QCDR Measure","Outcome","Y","","","5.0 - 98.21","98.22 - 99.31","99.32 - 99.68","99.69 - 99.84","99.85 - 99.94","99.95 - 99.99","--","100.0","No","","Y"
"Otitis Media with Effusion: Hearing Test for Chronic OME > 3 months","AAO21","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Benign Positional Paroxysmal Vertigo (BPPV): Dix-Hallpike and Canalith Repositioning","AAO35","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Sepsis: Hour One bundle","ACQR13","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Team-Based Implementation of a Care-and-Communication Bundle for ICU Patients","AQI55","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Intraoperative Antibiotic Redosing","AQI69","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Refractive Surgery: Patients with a postoperative uncorrected visual acuity (UCVA) of 20/20 or better within 30 days","IRIS23","QCDR Measure","Outcome","Y","","","42.78 - 68.74","68.75 - 75.33","75.34 - 79.91","79.92 - 83.01","83.02 - 87.79","87.8 - 89.18","89.19 - 94.11",">= 94.12","No","","Y"
"""Failure to Progress (FTP): Proportion of patients failing to achieve a Minimal Clinically Important Difference (MCID) in improvement in pain score, measured via the Numeric Pain Rating Scale (NPRS), in rehabilitation patients with neck pain/injury.""","IROMS16","QCDR Measure","Outcome","Y","","","47.06 - 45.25","45.24 - 43.49","43.48 - 42.56","42.55 - 41.6","41.59 - 40.17","40.16 - 38.97","38.96 - 38.06","<= 38.05","No","","Y"
"CHANGE IN PATIENT REPORTED QUALITY OF LIFE FOLLOWING INTRATHECAL PUMP IMPLANTATION","NIPM24","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Quality of Life - Physical Health Outcomes","OBERD32","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Diabetes Care All or None Outcome Measure: Optimal Control","WCHQ10","","Intermediate Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Melanoma: Coordination of Care","138","QCDR Measure","Process","Y","","","0.2 - 74.99","75.0 - 92.14","92.15 - 98.66","98.67 - 99.99","--","--","--","100.0","No","","Y"
"Functional Status Change for Patients with Low Back Impairments","220","QCDR Measure","patientReportedOutcome","Y","","","12.68 - 91.29","91.3 - 94.21","94.22 - 95.55","95.56 - 97.29","97.3 - 99.21","99.22 - 99.99","--","100.0","No","","Y"
"Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Routine Testing After Percutaneous Coronary Intervention (PCI)","323","QCDR Measure","Efficiency and Cost/Resource Use","Y","","","0.15 - 0.01","--","--","--","--","--","--","0.0","No","","Y"
"Maternity Care: Elective Delivery or Early Induction Without Medical Indication at < 39 Weeks (Overuse)","335","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"""Psoriasis: Tuberculosis (TB) Prevention for Patients with Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis on a Biological Immune Response Modifier""","337","QCDR Measure","Process","Y","","","0.57 - 68.56","68.57 - 81.47","81.48 - 89.21","89.22 - 94.5","94.51 - 97.58","97.59 - 99.99","--","100.0","No","","N"
"Total Knee Replacement: Venous Thromboembolic and Cardiovascular Risk Evaluation","351","QCDR Measure","Process","Y","","","1.75 - 99.28","99.29 - 99.99","--","--","--","--","--","100.0","No","","Y"
"Annual Hepatitis C Virus (HCV) Screening for Patients who are Active Injection Drug Users","387","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Opioid Therapy Follow-up Evaluation","408","QCDR Measure","Process","Y","","","0.21 - 75.21","75.22 - 92.15","92.16 - 98.7","98.71 - 99.96","99.97 - 99.99","--","--","100.0","No","","Y"
"Standard BPPV Management","AAO32","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Person-Centered Primary Care Measure Performance Measure (PCPCM PRO-PM)","ABFM11","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 18 Years and Older","ACEP19","QCDR Measure","Process","Y","","","35.71 - 53.09","53.1 - 55.18","55.19 - 58.38","58.39 - 60.27","60.28 - 63.28","63.29 - 64.96","64.97 - 68.41",">= 68.42","No","","Y"
"Antibiotic Prophylaxis for High Risk Cardiac / Orthopedic Cases prior to Mohs micrographic surgery - Prevention of Overuse","ACMS3","QCDR Measure","Process","Y","","","1.74 - 72.27","72.28 - 80.94","80.95 - 86.08","86.09 - 88.29","88.3 - 93.56","93.57 - 95.88","95.89 - 97.14",">= 97.15","No","","Y"
"Safe Hydroxychloroquine Dosing","ACR15","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Stones: Inappropriate Repeat Shock Wave Lithotripsy (SWL) Within 6 Months of Initial Treatment","AQUA14","QCDR Measure","Outcome","Y","","","48.65 - 41.29","41.28 - 38.72","38.71 - 34.49","34.48 - 31.48","31.47 - 28.42","28.41 - 21.37","21.36 - 13.8","<= 13.79","No","","Y"
"Breast Reconstruction: Return to OR","ASPS5","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Improved Visual Acuity after Vitrectomy for Complications of Diabetic Retinopathy within 120 Days","IRIS58","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"""Failure to Progress (FTP): Proportion of patients failing to achieve a Minimal Clinically Important Difference (MCID) to indicate functional improvement in rehabilitation of patients with arm, shoulder, and hand injury measured via the validated Disability of Arm Shoulder and Hand (DASH) score, Quick Disability of Arm Shoulder and Hand (QDASH) score, or equivalent instrument which has undergone peer reviewed published validation and demonstrates a peer reviewed published MCID.""","IROMS19","QCDR Measure","Outcome","Y","","","30.56 - 28.34","28.33 - 27.21","27.2 - 25.77","25.76 - 24.69","24.68 - 23.59","23.58 - 22.74","22.73 - 20.91","<= 20.9","No","","Y"
"Patient Feedback of Test Results Following Cognitive or Mental Status Assessment","MBHR12","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Notification to the provider ordering repeat CBCs in clinically stable patients within four days","NPQR18","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Arteriovenous Fistulae Thrombectomy Success Rate","RPAQIR15","QCDR Measure","Outcome","Y","","","60.0 - 78.34","78.35 - 81.64","81.65 - 82.67","82.68 - 84.19","84.2 - 86.06","86.07 - 90.99","91.0 - 91.68",">= 91.69","No","","Y"
"Communication with the Physician or Other Clinician Managing On-Going Care Post-Fracture for Men and Women Aged 50 Years and Older","24","QCDR Measure","Process","Y","","","0.19 - 14.72","14.73 - 59.99","60.0 - 78.06","78.07 - 82.87","82.88 - 87.87","87.88 - 93.47","93.48 - 99.79",">= 99.8","No","","Y"
"Communication with the Physician or Other Clinician Managing On-Going Care Post-Fracture for Men and Women Aged 50 Years and Older","24","Medicare Part B Claims","Process","Y","","","33.33 - 79.3","79.31 - 94.23","94.24 - 96.07","96.08 - 99.99","--","--","--","100.0","No","","Y"
"Rheumatoid Arthritis (RA): Functional Status Assessment","178","QCDR Measure","Process","Y","","","0.23 - 78.67","78.68 - 91.64","91.65 - 95.1","95.11 - 97.85","97.86 - 99.31","99.32 - 99.99","--","100.0","No","","N"
"Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention","226","Medicare Part B Claims","Process","Y","","","1.45 - 81.81","81.82 - 92.83","92.84 - 96.59","96.6 - 99.99","--","--","--","100.0","No","","N"
"Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention","226","eCQM","Process","Y","","","0.06 - 16.66","16.67 - 24.04","24.05 - 33.08","33.09 - 44.91","44.92 - 59.99","60.0 - 75.85","75.86 - 89.71",">= 89.72","No","","N"
"Radical Prostatectomy Pathology Reporting","250","Medicare Part B Claims","Process","Y","","","32.08 - 99.99","--","--","--","--","--","--","100.0","No","","N"
"Radical Prostatectomy Pathology Reporting","250","QCDR Measure","Process","Y","","","92.21 - 99.99","--","--","--","--","--","--","100.0","No","","N"
"Falls: Screening for Future Fall Risk","318","eCQM","Process","Y","","","0.01 - 18.26","18.27 - 36.22","36.23 - 51.97","51.98 - 66.12","66.13 - 78.19","78.2 - 87.13","87.14 - 93.98",">= 93.99","No","","Y"
"CAHPS for MIPs Clinician/Group Survey","321","","Patient Engagement/Experience","N","","","--","--","--","--","--","--","--","--","No","","Y"
"HIV Medical Visit Frequency","340","QCDR Measure","Process","Y","","","37.42 - 53.95","53.96 - 69.37","69.38 - 73.99","74.0 - 77.15","77.16 - 91.66","91.67 - 98.47","98.48 - 99.99","100.0","No","","Y"
"Lung Cancer Reporting (Biopsy/Cytology Specimens)","395","QCDR Measure","Process","Y","","","2.01 - 99.99","--","--","--","--","--","--","100.0","No","","Y"
"Lung Cancer Reporting (Biopsy/Cytology Specimens)","395","Medicare Part B Claims","Process","Y","","","75.0 - 99.99","--","--","--","--","--","--","100.0","No","","Y"
"Proportion of Patients Sustaining a Ureter Injury at the Time of Pelvic Organ Prolapse Repair","434","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Documentation of High-Risk Squamous Cell Carcinoma Stage in Mohs Micrographic Surgery Record","ACMS5","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"""Cancer Protocol and Turnaround Time for Gastrointestinal Carcinomas: Gastric, Esophageal, Colorectal and Hepatocellular Carcinomas""","CAP35","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Endothelial Keratoplasty – Dislocation Requiring Surgical Intervention","IRIS38","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Idiopathic Intracranial Hypertension: Improvement of mean deviation or stability of mean deviation","IRIS57","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Failure to Progress (FTP): Proportion of patients failing to achieve a Minimal Clinically Important Difference (MCID) to indicate functional improvement in rehabilitation of patients with neck pain/injury measured via the validated Neck Disability Index (NDI).","IROMS15","QCDR Measure","Outcome","Y","","","47.06 - 46.04","46.03 - 44.01","44.0 - 43.19","43.18 - 42.02","42.01 - 40.92","40.91 - 39.3","39.29 - 35.72","<= 35.71","No","","Y"
"Cognitive Assessment with Counseling on Safety and Potential Risk","MBHR11","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Alcohol Use Disorder Outcome Response","MBHR8","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Coronary Artery Disease (CAD): Antiplatelet Therapy","6","QCDR Measure","Process","Y","","","0.87 - 77.26","77.27 - 82.71","82.72 - 86.66","86.67 - 89.99","90.0 - 93.08","93.09 - 95.73","95.74 - 98.86",">= 98.87","No","","N"
"Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older","50","Medicare Part B Claims","Process","Y","","","2.9 - 96.66","96.67 - 99.99","--","--","--","--","--","100.0","No","","Y"
"Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older","50","QCDR Measure","Process","Y","","","0.18 - 61.15","61.16 - 77.64","77.65 - 85.7","85.71 - 91.15","91.16 - 96.14","96.15 - 99.89","99.9 - 99.99","100.0","No","","Y"
"Appropriate Testing for Pharyngitis","66","eCQM","Process","Y","","","0.28 - 69.99","70.0 - 79.81","79.82 - 85.49","85.5 - 89.22","89.23 - 93.47","93.48 - 97.25","97.26 - 99.99","100.0","No","","Y"
"Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care","141","QCDR Measure","Outcome","Y","","","0.04 - 33.04","33.05 - 60.51","60.52 - 83.16","83.17 - 93.65","93.66 - 98.6","98.62 - 99.99","--","100.0","No","","Y"
"Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care","141","Medicare Part B Claims","Outcome","Y","","","2.74 - 99.99","--","--","--","--","--","--","100.0","No","","Y"
"Radiology: Exposure Dose Indices or Exposure Time and Number of Images Reported for Procedures Using Fluoroscopy","145","QCDR Measure","Process","Y","","","0.11 - 86.8","86.81 - 95.65","95.66 - 98.53","98.54 - 99.87","99.88 - 99.99","--","--","100.0","No","","Y"
"Radiology: Exposure Dose Indices or Exposure Time and Number of Images Reported for Procedures Using Fluoroscopy","145","Medicare Part B Claims","Process","Y","","","0.38 - 85.32","85.33 - 94.58","94.59 - 97.62","97.63 - 99.18","99.19 - 99.99","--","--","100.0","No","","Y"
"Cardiac Rehabilitation Patient Referral from an Outpatient Setting","243","QCDR Measure","Process","Y","","","3.39 - 19.64","19.65 - 26.46","26.47 - 33.75","33.76 - 37.95","37.96 - 43.66","43.67 - 50.2","50.21 - 64.67",">= 64.68","No","","Y"
"Proportion of Patients Sustaining a Bladder Injury at the Time of any Pelvic Organ Prolapse Repair","432","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Allergic Rhinitis: Intranasal Corticosteroids or Oral Antihistamines","AAO23","QCDR Measure","Process","Y","","","13.33 - 61.7","61.71 - 68.11","68.12 - 71.02","71.03 - 73.33","73.34 - 75.84","75.85 - 77.57","77.58 - 80.76",">= 80.77","No","","N"
"Appropriate Treatment for Adults with Upper Respiratory Infection (URI)","ACEP58","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Coordination of Care for Anticoagulated Patients Undergoing Reconstruction After Skin Cancer Resection","ASPS22","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Urinary Bladder Biopsy Diagnostic Requirements For Appropriate Patient Management","CAP30","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Avoidance of Opiates for Low Back Pain or Migraines","ECPR46","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Opioid Withdrawal: Initiation of Medication-Assisted Treatment (MAT) and Referral to Outpatient Opioid Treatment","ECPR56","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Intraoperative Hypotension among Non-Emergent Noncardiac Surgical Cases","EPREOP31","","Intermediate Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"CHANGE IN PATIENT REPORTED PAIN AND FUNCTIONAL STATUS FOLLOWING SPINAL CORD STIMULATOR IMPLANTATION","NIPM20","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Notification to the ordering provider requesting amylase testing in the diagnosis of suspected acute pancreatitis","NPQR3","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Patient Reported Experience of Care: Wound Outcome","USWR24","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Coronary Artery Disease (CAD): Beta-Blocker Therapy – Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%)","7","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Prostate Cancer: Combination Androgen Deprivation Therapy for High Risk or Very High Risk Prostate Cancer","104","QCDR Measure","Process","Y","","","29.41 - 95.99","96.0 - 99.6","99.61 - 99.99","--","--","--","--","100.0","No","","N"
"Melanoma Reporting","397","QCDR Measure","Process","Y","","","3.03 - 99.99","--","--","--","--","--","--","100.0","No","","Y"
"Melanoma Reporting","397","Medicare Part B Claims","Process","Y","","","81.82 - 99.99","--","--","--","--","--","--","100.0","No","","Y"
"Achievement of Projected Effective Dose of Standardized Allergens for Patient Treated With Allergen Immunotherapy for at Least One Year","AAAAI8","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Querying About Symptoms of Autonomic Dysfunction for Patients with Parkinson's Disease","AAN9","QCDR Measure","Process","Y","","","6.25 - 53.69","53.7 - 62.95","62.96 - 81.21","81.22 - 86.56","86.57 - 89.28","89.29 - 92.66","92.67 - 96.27",">= 96.28","No","","N"
"Tobacco Use: Screening and Cessation Intervention for Patients with Asthma and COPD","ACEP25","QCDR Measure","Process","Y","","","25.03 - 58.68","58.69 - 67.82","67.83 - 70.91","70.92 - 72.91","72.92 - 76.11","76.12 - 77.26","77.27 - 79.13",">= 79.14","No","","N"
"""Sepsis Management: Septic Shock: Lactate Level Measurement, Antibiotics Ordered, and Fluid Resuscitation""","ACEP48","QCDR Measure","Process","Y","","","46.88 - 83.62","83.63 - 85.95","85.96 - 87.49","87.5 - 89.38","89.39 - 90.53","90.54 - 91.99","92.0 - 93.27",">= 93.28","No","","N"
"Use of Structured Reporting in Prostate MRI","ACRAD40","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Obstructive Sleep Apnea: Mitigation Strategies","AQI68","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Outcomes of Treatment of Subjective Tinnitus","HM11","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Failure to Progress (FTP): Proportion of patients failing to achieve a Minimal Clinically Important Difference (MCID) to indicate functional improvement in rehabilitation patients with low back pain measured via the validated Modified Low Back Pain Disability Questionnaire (MDQ) score.","IROMS17","QCDR Measure","Outcome","Y","","","41.47 - 37.96","37.95 - 36.26","36.25 - 35.27","35.26 - 34.65","34.64 - 33.59","33.58 - 32.53","32.52 - 31.21","<= 31.2","No","","Y"
"Use of a “PEG Test” to Manage Patients Receiving Opioids","MEDNAX56","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"CHANGE IN PATIENT REPORTED QUALITY OF LIFE FOLLOWING EPIDURAL LYSIS OF ADHESIONS","NIPM18","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Use of ultrasound guidance for vascular access","OEIS8","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Heel Pain Treatment Outcomes for Adults","REGCLR1","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Offloading with Remote Monitoring","REGCLR5","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Preventive Care and Screening: Influenza Immunization","110","eCQM","Process","Y","","","0.0 - 22.61","22.62 - 32.67","32.68 - 41.56","41.57 - 49.48","49.49 - 57.49","57.5 - 67.6","67.61 - 80.12",">= 80.13","No","","N"
"Preventive Care and Screening: Influenza Immunization","110","Medicare Part B Claims","Process","Y","","","0.08 - 63.09","63.1 - 75.53","75.54 - 85.16","85.17 - 92.9","92.91 - 97.97","97.98 - 99.87","99.88 - 99.99","100.0","No","","N"
"Radiology: Inappropriate Use of “Probably Benign” Assessment Category in Screening Mammograms","146","Medicare Part B Claims","Process","Y","","","0.79 - 0.34","0.33 - 0.15","0.14 - 0.01","--","--","--","--","0.0","No","","Y"
"Radiology: Inappropriate Use of “Probably Benign” Assessment Category in Screening Mammograms","146","QCDR Measure","Process","Y","","","0.54 - 0.18","0.17 - 0.09","0.08 - 0.03","0.02 - 0.01","--","--","--","0.0","No","","Y"
"Falls: Plan of Care","155","Medicare Part B Claims","Process","Y","","","0.79 - 85.7","85.71 - 97.82","97.83 - 99.99","--","--","--","--","100.0","No","","Y"
"Falls: Plan of Care","155","QCDR Measure","Process","Y","","","0.14 - 86.22","86.23 - 93.95","93.96 - 97.95","97.96 - 99.99","--","--","--","100.0","No","","Y"
"Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure","167","QCDR Measure","Outcome","Y","","","4.29 - 3.21","3.2 - 2.21","2.2 - 1.9","1.89 - 1.53","1.52 - 1.29","1.28 - 0.94","0.93 - 0.54","<= 0.53","No","","Y"
"Coronary Artery Bypass Graft (CABG): Surgical Re-Exploration","168","QCDR Measure","Outcome","Y","","","7.27 - 4.18","4.17 - 2.64","2.63 - 2.2","2.19 - 1.56","1.55 - 1.22","1.21 - 0.49","0.48 - 0.01","0.0","No","","Y"
"""Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Testing in Asymptomatic, Low-Risk Patients""","324","QCDR Measure","Efficiency and Cost/Resource Use","Y","","","9.31 - 3.97","3.96 - 0.91","0.9 - 0.01","--","--","--","--","0.0","No","","Y"
"HIV Viral Load Suppression","338","QCDR Measure","Outcome","Y","","","2.86 - 80.34","80.35 - 86.08","86.09 - 89.86","89.87 - 92.85","92.86 - 95.43","95.44 - 97.95","97.96 - 99.99","100.0","No","","Y"
"Skin Cancer Surgery: Post-Operative Complications","AAD11","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Psoriasis – Improvement in Patient-Reported Itch Severity","AAD9","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Heart Failure: Patient Self Care Education","ACCPIN11","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Abdominal Wall Reconstruction Surgical Site Occurrence Requiring Procedural Intervention within the 30 Day Postoperative Period","AHSQC6","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Safe Opioid Prescribing Practices","AQI57","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Discharge Prescription of Naloxone after Opioid Poisoning or Overdose","ECPR51","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Avoidance of Echocardiogram and Carotid Ultrasound for Syncope","HCPR23","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Transthoracic Echo (TTE) performance per ASE guidelines","IGR10","","Efficiency","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Chronic Anterior Uveitis - Post-treatment visual acuity","IRIS53","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Oncology: Utilization of GCSF in metastatic colorectal cancer","PIMSH2","","Efficiency","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Ankylosing Spondylitis: Appropriate Pharmacologic Therapy","UREQA2","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Folic or Folinic Acid Therapy for Patients Treated with Methotrexate","UREQA4","QCDR Measure","Process","Y","","","40.28 - 90.2","90.21 - 92.9","92.91 - 94.21","94.22 - 94.97","94.98 - 97.29","97.3 - 97.95","97.96 - 98.7",">= 98.71","No","","N"
"Patient Reported Nutritional Assessment in Patients with Wounds and Ulcers","USWR22","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy – Avoidance of Inappropriate Use","93","Medicare Part B Claims","Process","Y","","","12.86 - 93.06","93.07 - 96.04","96.05 - 98.05","98.06 - 99.99","--","--","--","100.0","No","","Y"
"Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy – Avoidance of Inappropriate Use","93","QCDR Measure","Process","Y","","","5.84 - 83.74","83.75 - 89.22","89.23 - 92.67","92.68 - 95.41","95.42 - 97.15","97.16 - 98.6","98.61 - 99.99","100.0","No","","Y"
"Breast Cancer Screening","112","Medicare Part B Claims","Process","Y","","","0.75 - 65.43","65.44 - 76.59","76.6 - 85.03","85.04 - 90.01","90.02 - 93.68","93.69 - 97.32","97.33 - 99.0",">= 99.01","No","","N"
"Breast Cancer Screening","112","eCQM","Process","Y","","","0.01 - 23.69","23.7 - 37.07","37.08 - 46.42","46.43 - 54.62","54.63 - 61.39","61.4 - 67.65","67.66 - 74.49",">= 74.5","No","","N"
"Functional Status Change for Patients with Shoulder Impairments","221","QCDR Measure","patientReportedOutcome","Y","","","59.21 - 95.24","95.25 - 96.79","96.8 - 97.91","97.92 - 99.23","99.24 - 99.99","--","--","100.0","No","","Y"
"""Infection within 180 Days of Cardiac Implantable Electronic Device (CIED) Implantation, Replacement, or Revision""","393","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Risk-Adjusted Operative Mortality for Coronary Artery Bypass Graft (CABG)","445","QCDR Measure","Outcome","Y","","","5.0 - 4.24","4.23 - 2.64","2.63 - 2.12","2.11 - 1.48","1.47 - 0.9","0.89 - 0.01","--","0.0","No","","Y"
"Prevention of Post-Operative Vomiting (POV) – Combination Therapy (Pediatrics)","463","QCDR Measure","Process","Y","","","24.19 - 94.88","94.89 - 97.32","97.33 - 98.28","98.29 - 99.1","99.11 - 99.66","99.67 - 99.99","--","100.0","No","","Y"
"Appropriate Foley catheter use in the emergency department","ACEP31","QCDR Measure","Process","Y","","","31.56 - 48.43","48.44 - 54.35","54.36 - 57.2","57.21 - 73.9","73.91 - 75.24","75.25 - 77.77","77.78 - 85.25",">= 85.26","No","","Y"
"Adequate Compression at each visit for Patients with VLUs","CDR5","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Venous Leg Ulcer (VLU) outcome measure: Healing or Closure","CDR6","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Intraocular Pressure Reduction Following Trabeculectomy or an Aqueous Shunt Procedure","IRIS39","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Evidence of anatomic closure of macular hole within 90 days after surgery as documented by OCT","IRIS46","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"""Failure to Progress (FTP): Proportion of patients failing to achieve a Minimal Clinically Important Difference (MCID) to indicate functional improvement in knee rehabilitation of patients with knee injury measured via their validated Knee Outcome Survey (KOS) score, or equivalent instrument which has undergone peer reviewed published validation and demonstrates a peer reviewed published MCID.""","IROMS11","QCDR Measure","Outcome","Y","","","48.1 - 40.99","40.98 - 32.44","32.43 - 30.01","30.0 - 27.53","27.52 - 25.98","25.97 - 23.88","23.87 - 22.23","<= 22.22","No","","Y"
"Time interval: critical value reporting for troponin","NPQR7","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Structured Walking Program Prior to Intervention for Claudication","OEIS7","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Central Line Ultrasound Guidance","QUANTUM31","QCDR Measure","Process","Y","","","13.17 - 89.45","89.46 - 96.33","96.34 - 98.25","98.26 - 99.17","99.18 - 99.99","--","--","100.0","No","","Y"
"Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)","8","eCQM","Process","Y","","","2.99 - 88.88","88.89 - 92.49","92.5 - 94.8","94.81 - 96.14","96.15 - 97.64","97.65 - 99.79","99.8 - 99.99","100.0","No","","N"
"Functional Status Change for Patients with Hip Impairments","218","QCDR Measure","patientReportedOutcome","Y","","","13.44 - 93.32","93.33 - 95.27","95.28 - 98.05","98.06 - 99.78","99.79 - 99.99","--","--","100.0","No","","Y"
"Sentinel Lymph Node Biopsy for Invasive Breast Cancer","264","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Hepatitis C: Discussion and Shared Decision Making Surrounding Treatment Options","390","QCDR Measure","Process","Y","","","1.55 - 11.51","11.52 - 39.57","39.58 - 69.24","69.25 - 90.47","90.48 - 97.59","97.6 - 99.99","--","100.0","No","","Y"
"Door to Puncture Time for Endovascular Stroke Treatment","413","","Intermediate Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Multimodal Pain Management","477","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Functional Status Change for Patients with Neck Impairments","478","","patientReportedOutcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Diabetes/Pre-Diabetes Screening for Patients with DSP","AAN28","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Tympanostomy Tubes: Topical Ear Drop Monotherapy Acute Otorrhea","AAO12","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Appropriate Utilization of FAST Exam in the Emergency Department","ACEP54","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"""Avoidance of Opioid therapy for migraine, low back pain, dental pain""","ACEP57","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Limit quantity of opioids prescribed for pain management in patients following Mohs micrographic surgery","ACMS8","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Patient Satisfaction with Information Provided during Breast Reconstruction","ASPS10","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Airway Assessment for patients undergoing Rhinoplasty","ASPS16","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Patient-Reported Pain and/or Function Improvement after Total Hip Arthroplasty","CCOME7","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Clinician Reporting of Loss of Consciousness to State Department of Public Health or Department of Motor Vehicles","ECPR53","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Intraocular Pressure Reduction Following Laser Trabeculoplasty","IRIS43","QCDR Measure","Outcome","Y","","","14.29 - 21.42","21.43 - 27.49","27.5 - 30.52","30.53 - 33.32","33.33 - 38.97","38.98 - 62.85","62.86 - 70.96",">= 70.97","No","","Y"
"Percent of patients meeting SCB thresholds for back or neck pain","SPINETRACK4","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan","128","eCQM","Process","Y","","","0.01 - 24.1","24.11 - 29.13","29.14 - 36.33","36.34 - 47.89","47.9 - 64.05","64.06 - 79.99","80.0 - 91.64",">= 91.65","No","","N"
"Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan","128","Medicare Part B Claims","Process","Y","","","0.07 - 90.44","90.45 - 98.4","98.41 - 99.68","99.69 - 99.99","--","--","--","100.0","No","","N"
"Barrett’s Esophagus","249","QCDR Measure","Process","Y","","","57.76 - 99.99","--","--","--","--","--","--","100.0","No","","N"
"Barrett’s Esophagus","249","Medicare Part B Claims","Process","Y","","","93.75 - 99.99","--","--","--","--","--","--","100.0","No","","N"
"Surgical Site Infection (SSI)","357","QCDR Measure","Outcome","Y","","","9.4 - 3.61","3.6 - 2.0","1.99 - 0.88","0.87 - 0.01","--","--","--","0.0","No","","Y"
"Optimizing Patient Exposure to Ionizing Radiation: Count of Potential High Dose Radiation Imaging Studies: Computed Tomography (CT) and Cardiac Nuclear Medicine Studies","360","QCDR Measure","Process","Y","","","0.01 - 85.5","85.51 - 98.23","98.24 - 99.93","99.94 - 99.99","--","--","--","100.0","No","","Y"
"Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment","382","eCQM","Process","Y","","","0.04 - 7.3","7.31 - 12.49","12.5 - 18.96","18.97 - 29.59","29.6 - 38.72","38.73 - 46.66","46.67 - 57.56",">= 57.57","No","","Y"
"Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 2 Through 17 Years","416","QCDR Measure","Efficiency and Cost/Resource Use","Y","","","45.62 - 27.5","27.49 - 20.72","20.71 - 12.51","12.5 - 5.98","5.97 - 3.46","3.45 - 2.05","2.04 - 0.01","0.0","No","","Y"
"Quality of Life Assessment For Patients With Primary Headache Disorders","435","QCDR Measure","patientReportedOutcome","Y","","","0.02 - 0.91","0.92 - 2.75","2.76 - 22.6","22.61 - 84.08","84.09 - 94.16","94.17 - 99.99","--","100.0","No","","Y"
"Age Appropriate Screening Colonoscopy","439","QCDR Measure","Efficiency and Cost/Resource Use","Y","","","80.5 - 52.9","52.89 - 2.51","2.5 - 0.01","--","--","--","--","0.0","No","","Y"
"Patients with Metastatic Colorectal Cancer and RAS (KRAS or NRAS) Gene Mutation Spared Treatment with Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies","452","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 2 Through 17 Years","ACEP55","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Use of ACE-I or ARB and beta blockade in CHF","ACQR9","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Gout: Serum Urate Target","ACR14","","Intermediate Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Rh Status Evaluation and Treatment of Pregnant Women at Risk of Fetal Blood Exposure","ECPR41","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Endothelial Keratoplasty - Post-operative improvement in best corrected visual acuity to 20/40 or better","IRIS1","QCDR Measure","Outcome","Y","","","17.86 - 38.74","38.75 - 46.14","46.15 - 48.71","48.72 - 55.87","55.88 - 56.39","56.4 - 66.98","66.99 - 71.78",">= 71.79","No","","Y"
"Regaining Vision After Cataract Surgery","IRIS59","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"""Failure to Progress (FTP): Proportion of patients failing to achieve a Minimal Clinically Important Difference (MCID) in improvement in pain score, measured via the Numeric Pain Rating Scale (NPRS), in rehabilitation patients with low back pain.""","IROMS18","QCDR Measure","Outcome","Y","","","49.19 - 46.63","46.62 - 45.4","45.39 - 44.06","44.05 - 43.68","43.67 - 43.09","43.08 - 42.29","42.28 - 41.19","<= 41.18","No","","Y"
"Kidney Stones: Opioid utilization after ureteroscopy and shockwave lithotripsy","MUSIC17","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Prostate Cancer: Opioid utilization after radical prostatectomy","MUSIC21","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Notification to the provider ordering repeat Hepatitis C serology testing on a patient with previously positive results","NPQR19","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Oncology: Mutation testing for lung cancer completed prior to start of targeted therapy","PIMSH8","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Appropriate Documentation of a Malnutrition Diagnosis","PINC55","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis","116","QCDR Measure","Process","Y","","","2.78 - 62.97","62.98 - 75.57","75.58 - 86.24","86.25 - 93.21","93.22 - 96.76","96.77 - 98.26","98.27 - 99.59",">= 99.6","No","","Y"
"""HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia, Gonorrhea, and Syphilis""","205","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Anastomotic Leak Intervention","354","QCDR Measure","Outcome","Y","","","6.52 - 3.71","3.7 - 2.01","2.0 - 0.23","0.22 - 0.01","--","--","--","0.0","No","","Y"
"Functional Status Assessment for Total Knee Replacement","375","eCQM","Process","Y","","","0.12 - 6.36","6.37 - 10.31","10.32 - 13.59","13.6 - 20.88","20.89 - 28.7","28.71 - 37.49","37.5 - 51.59",">= 51.6","No","","Y"
"Pelvic Organ Prolapse: Preoperative Screening for Uterine Malignancy","429","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Leg Pain After Lumbar Discectomy/Laminectomy","461","","patientReportedOutcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Surgical Site Infection Rate - Mohs Micrographic Surgery","ACMS4","QCDR Measure","Outcome","Y","","","1.91 - 1.27","1.26 - 1.09","1.08 - 0.89","0.88 - 0.61","0.6 - 0.28","0.27 - 0.14","0.13 - 0.09","<= 0.08","No","","Y"
"Incidental Coronary Artery Calcification Reported on Chest CT","ACRAD36","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Hip Arthroplasty: Shared Decision-Making: Trial of Conservative (Non-surgical) Therapy","AJRR3","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Hospital admissions/complications within 30 days of TRUS Biopsy","AQUA8","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"""Parameters in stress echocardiography dobutamine testing for low flow, low gradient aortic stenosis""","IGR2","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Stress echo performance for shortness of breath per ASE guidelines","IGR9","","Efficiency","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Patient Reported Health-Related Quality of Life (HRQoL) during Treatment for Advanced Cancer","ONSQIR21","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Transplant Referral","RPAQIR5","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Functional Status Change for Patients with Knee Impairments","217","QCDR Measure","patientReportedOutcome","Y","","","16.74 - 95.22","95.23 - 96.58","96.59 - 98.22","98.23 - 99.52","99.53 - 99.99","--","--","100.0","No","","Y"
"Parkinson’s Disease: Psychiatric Symptoms Assessment for Patients with Parkinson’s Disease","290","QCDR Measure","Process","Y","","","1.15 - 36.35","36.36 - 57.46","57.47 - 81.07","81.08 - 91.95","91.96 - 98.84","98.85 - 99.99","--","100.0","No","","N"
"Parkinson’s Disease: Rehabilitative Therapy Options","293","QCDR Measure","Process","Y","","","0.4 - 40.62","40.63 - 62.89","62.9 - 84.61","84.62 - 92.97","92.98 - 99.99","--","--","100.0","No","","Y"
"Clinical Outcome Post Endovascular Stroke Treatment","409","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Asthma Control: Minimal Important Difference Improvement","AAAAI17","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Penicillin Allergy: Appropriate Removal or Confirmation","AAAAI18","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Pediatric Medication reconciliation","AAN25","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Allergic Rhinitis: Avoidance of Leukotriene Inhibitors","AAO24","QCDR Measure","Process","Y","","","57.75 - 82.84","82.85 - 85.63","85.64 - 87.89","87.9 - 91.67","91.68 - 93.48","93.49 - 96.04","96.05 - 96.89",">= 96.9","No","","Y"
"Use of Low Dose Cranial CT or MRI Examinations for Patients with Ventricular Shunts","ACRAD38","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Patient Satisfaction with Information Prior to Facial Reconstruction After Skin Cancer Resection Procedures","ASPS26","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Patient-Reported Pain and/or Function Improvement after Total Knee Arthroplasty","CCOME1","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Pre operative ultrasound exam of patients with thyroid cancer","CESQIP3","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Door to Diagnostic Evaluation by a Provider Within 30 Minutes – Urgent Care Patients","ECPR50","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Surgical Pediatric Esotropia: Postoperative alignment","IRIS49","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Adult Diplopia: Improvement of ocular deviation or absence of diplopia or functional improvement","IRIS56","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Hammer Toe Outcome","MEX5","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Oncology: Supportive care drug utilization in last 14 days of life","PIMSH9","","Efficiency","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Assessment of Nutritionally At-Risk Patients for Malnutrition and Development of Nutrition Recommendations/Interventions by a Registered Dietitian Nutritionist","PINC56","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Advance Care Plan","47","QCDR Measure","Process","Y","","","0.01 - 20.15","20.16 - 43.37","43.38 - 64.15","64.16 - 78.63","78.64 - 89.0","89.01 - 95.52","95.53 - 98.84",">= 98.85","No","","Y"
"Advance Care Plan","47","Medicare Part B Claims","Process","Y","","","0.13 - 85.07","85.08 - 97.49","97.5 - 99.7","99.71 - 99.99","--","--","--","100.0","No","","Y"
"Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry","70","QCDR Measure","Process","Y","","","5.0 - 73.67","73.68 - 99.76","99.77 - 99.99","--","--","--","--","100.0","No","","N"
"Diabetes: Medical Attention for Nephropathy","119","eCQM","Process","Y","","","0.02 - 70.66","70.67 - 77.4","77.41 - 82.08","82.09 - 85.71","85.72 - 88.85","88.86 - 92.08","92.09 - 95.76",">= 95.77","No","","N"
"""Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy – Neurological Evaluation""","126","QCDR Measure","Process","Y","","","0.07 - 59.79","59.8 - 75.87","75.88 - 86.26","86.27 - 94.86","94.87 - 99.2","99.21 - 99.99","--","100.0","No","","N"
"Cervical Cancer Screening","309","eCQM","Process","Y","","","0.01 - 11.1","11.11 - 18.25","18.26 - 24.99","25.0 - 32.21","32.22 - 39.37","39.38 - 46.58","46.59 - 54.93",">= 54.94","No","","N"
"Tobacco Use and Help with Quitting Among Adolescents","402","QCDR Measure","Process","Y","","","0.18 - 88.24","88.25 - 93.64","93.65 - 96.68","96.69 - 98.54","98.55 - 99.57","99.58 - 99.99","--","100.0","No","","N"
"Overuse of Imaging for the Evaluation of Primary Headache","419","QCDR Measure","Process","Y","","","50.57 - 31.92","31.91 - 16.49","16.48 - 11.77","11.76 - 5.99","5.98 - 3.86","3.85 - 2.01","2.0 - 0.8","<= 0.79","No","","Y"
"Photodocumentation of Cecal Intubation","425","QCDR Measure","Process","Y","","","3.17 - 86.0","86.01 - 92.12","92.13 - 95.72","95.73 - 97.74","97.75 - 98.5","98.51 - 99.03","99.04 - 99.34",">= 99.35","No","","N"
"Photodocumentation of Cecal Intubation","425","Medicare Part B Claims","Process","Y","","","87.8 - 98.79","98.8 - 99.28","99.29 - 99.99","--","--","--","--","100.0","No","","N"
"Preventive Care and Screening: Unhealthy Alcohol Use: Screening & Brief Counseling","431","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Otitis Media with Effusion: Systemic Antimicrobials - Avoidance of Inappropriate Use","464","QCDR Measure","Process","Y","","","24.0 - 85.1","85.11 - 87.52","87.53 - 89.99","90.0 - 92.8","92.81 - 94.36","94.37 - 95.96","95.97 - 97.26",">= 97.27","No","","Y"
"Upper Extremity Nerve Blockade in Shoulder Surgery","ABG41","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Sepsis Management: Septic Shock: Lactate Clearance Rate of ≥ 10%","ACEP30","QCDR Measure","Outcome","Y","","","61.54 - 73.8","73.81 - 76.51","76.52 - 77.63","77.64 - 80.47","80.48 - 82.91","82.92 - 84.78","84.79 - 87.02",">= 87.03","No","","Y"
"Related readmission for adrenal related problems","CESQIP5","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Avoidance of Co-Prescribing of Opioid Analgesic and Benzodiazepine","ECPR54","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Appropriate follow-up interval based on pathology findings in screening colonoscopy","GIQIC23","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Functional Benefit of a Cochlear Implant","HM9","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Myocardial Perfusion Imaging (MPI) or Stress Echocardiography Imaging Studies - Adequate Exercise Protocol","IGR15","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Visual Acuity Improvement Following Cataract Surgery and Minimally Invasive Glaucoma Surgery","IRIS55","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Visual Acuity Improvement Following Cataract Surgery Combined with a Trabeculectomy or an Aqueous Shunt Procedure","IRIS60","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Use of Thyroid Imaging Reporting & Data System (TI-RADS) in Final Report to Stratify Thyroid Nodule Risk","MSN15","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Repeat screening or surveillance colonoscopy recommended within one year due to inadequate/poor bowel preparation","NHCR4","QCDR Measure","Process","Y","","","3.15 - 19.99","20.0 - 32.4","32.41 - 44.82","44.83 - 56.97","56.98 - 65.48","65.49 - 77.85","77.86 - 87.17",">= 87.18","No","","Y"
"Rate of notification to clinical provider of a new diagnosis of malignancy","NPQR13","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Rate of Timely Documentation Transmission to Dialysis Unit/Referring Physician","RPAQIR13","QCDR Measure","Process","Y","","","64.04 - 91.71","91.72 - 92.18","92.19 - 95.18","95.19 - 96.7","96.71 - 96.93","96.94 - 97.48","97.49 - 97.81",">= 97.82","No","","Y"
"Non Invasive Arterial Assessment of patients with lower extremity wounds or ulcers for determination of healing potential","USWR23","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Diabetes Care All or None Process Measure: Optimal Testing","WCHQ9","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Screening for Osteoporosis for Women Aged 65-85 Years of Age","39","QCDR Measure","Process","Y","","","0.04 - 12.83","12.84 - 28.2","28.21 - 39.77","39.78 - 50.99","51.0 - 61.17","61.18 - 69.03","69.04 - 78.47",">= 78.48","No","","N"
"Screening for Osteoporosis for Women Aged 65-85 Years of Age","39","Medicare Part B Claims","Process","Y","","","0.51 - 36.21","36.22 - 49.5","49.51 - 58.71","58.72 - 65.37","65.38 - 74.76","74.77 - 87.13","87.14 - 96.5",">= 96.51","No","","N"
"Chronic Obstructive Pulmonary Disease (COPD): Long-Acting Inhaled Bronchodilator Therapy","52","QCDR Measure","Process","Y","","","0.16 - 82.96","82.97 - 93.13","93.14 - 97.88","97.89 - 99.47","99.48 - 99.99","--","--","100.0","No","","N"
"Chronic Obstructive Pulmonary Disease (COPD): Long-Acting Inhaled Bronchodilator Therapy","52","Medicare Part B Claims","Process","Y","","","85.71 - 97.95","97.96 - 99.99","--","--","--","--","--","100.0","No","","N"
"Radiology: Stenosis Measurement in Carotid Imaging Reports","195","QCDR Measure","Process","Y","","","0.38 - 99.26","99.27 - 99.8","99.81 - 99.99","--","--","--","--","100.0","No","","N"
"Radiology: Stenosis Measurement in Carotid Imaging Reports","195","Medicare Part B Claims","Process","Y","","","8.7 - 97.82","97.83 - 99.38","99.39 - 99.99","--","--","--","--","100.0","No","","N"
"Ultrasound Determination of Pregnancy Location for Pregnant Patients with Abdominal Pain","254","QCDR Measure","Process","Y","","","52.57 - 88.56","88.57 - 92.05","92.06 - 95.23","95.24 - 96.76","96.77 - 98.15","98.16 - 99.11","99.12 - 99.99","100.0","No","","N"
"Depression Remission at Twelve Months","370","eCQM","Outcome","Y","","","0.34 - 3.6","3.61 - 4.9","4.91 - 6.24","6.25 - 7.45","7.46 - 9.51","9.52 - 11.9","11.91 - 14.8",">= 14.81","No","","Y"
"Immunizations for Adolescents","394","QCDR Measure","Process","Y","","","1.04 - 3.69","3.7 - 7.68","7.69 - 17.94","17.95 - 20.82","20.83 - 23.52","23.53 - 30.29","30.3 - 38.09",">= 38.1","No","","N"
"Percentage of Patients Who Died from Cancer Admitted to Hospice for Less than 3 days (lower score – better)","457","QCDR Measure","Outcome","Y","","","16.0 - 11.33","11.32 - 10.01","10.0 - 8.17","8.16 - 6.99","6.98 - 4.27","4.26 - 3.04","3.03 - 2.23","<= 2.22","No","","Y"
"Bone Density Evaluation for Patients with Prostate Cancer and Receiving Androgen Deprivation Therapy","462","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"""Multi-strata weighted average for 3 CT Exam Types: Overall Percent of CT exams for which Dose Length Product is at or below the size-specific diagnostic reference level (for CT Abdomen-pelvis with contrast/single phase scan, CT Chest without contrast/single phase scan and CT Head/Brain without contrast/single phase scan)""","ACRAD34","QCDR Measure","Outcome","Y","","","28.83 - 60.42","60.43 - 67.56","67.57 - 82.24","82.25 - 85.82","85.83 - 88.7","88.71 - 94.26","94.27 - 95.13",">= 95.14","No","","Y"
"Consultation for Frail Patients","AQI67","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Benign Prostate Hyperplasia (BPH): Inappropriate Lab & Imaging Services for Patients with BPH","AQUA26","QCDR Measure","Process","Y","","","25.84 - 13.04","13.03 - 11.26","11.25 - 8.51","8.5 - 6.47","6.46 - 5.01","5.0 - 3.09","3.08 - 1.21","<= 1.2","No","","Y"
"Avoidance of Post-operative Systemic Antibiotics for Office-based Closures and Reconstruction After Skin Cancer Procedures","ASPS27","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Patient-Reported Pain and/or Function Improvement after ACLR Surgery","CCOME4","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Adequate Off-loading of Diabetic Foot Ulcer at each visit","CDR1","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Prostate Cancer: Radical Prostatectomy Cases LOS","MUSIC5","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Tendinitis/ Enthesopathy- Injection Treatment Outcomes for Adults","REGCLR2","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Obtaining Preoperative Nutritional Recommendations from a Registered Dietitian Nutritionist (RDN) in Nutritionally At-Risk Surgical Patients","USWR28","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Documentation of Current Medications in the Medical Record","130","eCQM","Process","Y","","","0.01 - 84.25","84.26 - 92.43","92.44 - 96.08","96.09 - 97.99","98.0 - 99.11","99.12 - 99.68","99.69 - 99.92",">= 99.93","No","","Y"
"Documentation of Current Medications in the Medical Record","130","Medicare Part B Claims","Process","Y","","","0.07 - 99.67","99.68 - 99.92","99.93 - 99.99","--","--","--","--","100.0","No","","Y"
"Dementia Associated Behavioral and Psychiatric Symptoms Screening and Management","283","QCDR Measure","Process","Y","","","0.12 - 74.5","74.51 - 92.44","92.45 - 96.19","96.2 - 98.51","98.52 - 99.99","--","--","100.0","No","","N"
"Closing the Referral Loop: Receipt of Specialist Report","374","eCQM","Process","Y","","","0.02 - 10.12","10.13 - 18.13","18.14 - 27.06","27.07 - 37.97","37.98 - 49.99","50.0 - 65.92","65.93 - 81.63",">= 81.64","No","","Y"
"Psoriasis: Clinical Response to Systemic Medications","410","QCDR Measure","Outcome","Y","","","1.54 - 57.13","57.14 - 70.72","70.73 - 80.32","80.33 - 87.99","88.0 - 93.49","93.5 - 97.43","97.44 - 99.99","100.0","No","","Y"
"Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 18 Years and Older","415","QCDR Measure","Efficiency and Cost/Resource Use","Y","","","21.29 - 82.0","82.01 - 90.14","90.15 - 93.96","93.97 - 96.03","96.04 - 97.49","97.5 - 98.4","98.41 - 99.19",">= 99.2","No","","Y"
"Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 18 Years and Older","415","Medicare Part B Claims","Efficiency","Y","","","46.03 - 89.18","89.19 - 91.93","91.94 - 93.47","93.48 - 95.23","95.24 - 96.66","96.67 - 97.66","97.67 - 98.14",">= 98.15","No","","Y"
"Proportion of Patients Sustaining a Bowel Injury at the time of any Pelvic Organ Prolapse Repair","433","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Dysphonia: Postoperative Laryngeal Examination","AAO34","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Surveillance Imaging for Liver Nodules <10mm in Patients at Risk for Hepatocellular Carcinoma (HCC)","ACRAD42","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Hip/Knee Arthroplasty: Unplanned Readmission within 90 Days Following the Primary Procedure","AJRR6","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Adherence to Blood Conservation Guidelines for Cardiac Operations using Cardiopulmonary Bypass (CPB) – Composite","AQI49","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Continuation of Anticoagulation Therapy in the Office-based Setting for Closure and Reconstruction After Skin Cancer Resection Procedures","ASPS28","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Pressure Ulcers – Risk Assessment and Plan of Care","HCPR17","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Comprehensive TTE studies reporting a measured value of LVEF AND wall motion findings with LVEF < 50%","IGR1","","Efficiency","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Visual Field Progression in Glaucoma","IRIS44","QCDR Measure","Outcome","Y","","","16.92 - 15.6","15.59 - 14.55","14.54 - 13.14","13.13 - 12.12","12.11 - 10.92","10.91 - 9.53","9.52 - 8.94","<= 8.93","No","","Y"
"Screening Abdominal Aortic Aneurysm Reporting with Recommendations","MSN16","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Kidney Stones: Readmission within 30 days of ureteroscopy","MUSIC19","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"CHANGE IN PATIENT REPORTED QUALITY OF LIFE FOLLOWING MAJOR JOINT CORTICOSTEROID INJECTION","NIPM23","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Non-small cell lung carcinoma (NSCLC) ancillary biomarker testing status and turnaround time (TAT) from point of specimen accession date to ancillary biomarker testing completion and reporting date should be ≤ 10 days","NPQR15","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"DEXA/DXA and Fracture Risk Assessment for Patients with Osteopenia","QMM19","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Opening Pressure in Lumbar Puncture","QMM20","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Use of Digital Imaging to Monitor and Improve Treatment Outcomes in Chronic Wound Healing","REGCLR6","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Advance Directives Completed","RPAQIR18","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Age-Related Macular Degeneration (AMD): Dilated Macular Examination","14","QCDR Measure","Process","Y","","","0.07 - 86.5","86.51 - 91.93","91.94 - 95.08","95.09 - 97.0","97.01 - 98.57","98.58 - 99.58","99.59 - 99.99","100.0","No","","N"
"Age-Related Macular Degeneration (AMD): Dilated Macular Examination","14","Medicare Part B Claims","Process","Y","","","2.5 - 99.99","--","--","--","--","--","--","100.0","No","","N"
"Oncology: Medical and Radiation - Plan of Care for Pain","144","QCDR Measure","Process","Y","","","2.38 - 69.99","70.0 - 85.18","85.19 - 91.66","91.67 - 96.91","96.92 - 98.94","98.95 - 99.99","--","100.0","No","","Y"
"Tuberculosis Screening Prior to First Course Biologic Therapy","176","QCDR Measure","Process","Y","","","1.2 - 61.63","61.64 - 78.12","78.13 - 89.99","90.0 - 93.66","93.67 - 97.74","97.75 - 99.99","--","100.0","No","","N"
"Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity","177","QCDR Measure","Process","Y","","","0.13 - 65.91","65.92 - 76.73","76.74 - 85.8","85.82 - 91.11","91.12 - 95.22","95.23 - 98.22","98.23 - 99.76",">= 99.77","No","","N"
"Functional Outcome Assessment","182","Medicare Part B Claims","Process","Y","","","0.04 - 99.41","99.42 - 99.99","--","--","--","--","--","100.0","No","","Y"
"Functional Outcome Assessment","182","QCDR Measure","Process","Y","","","0.01 - 98.02","98.03 - 99.37","99.38 - 99.75","99.76 - 99.94","99.95 - 99.99","--","--","100.0","No","","Y"
"""Functional Status Change for Patients with Elbow, Wrist or Hand Impairments""","222","QCDR Measure","patientReportedOutcome","Y","","","35.16 - 95.5","95.51 - 96.98","96.99 - 98.22","98.23 - 99.99","--","--","--","100.0","No","","Y"
"Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented","317","eCQM","Process","Y","","","0.01 - 21.2","21.21 - 26.25","26.26 - 30.76","30.77 - 34.86","34.87 - 39.51","39.52 - 45.26","45.27 - 53.95",">= 53.96","No","","N"
"Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented","317","Medicare Part B Claims","Process","Y","","","0.09 - 90.87","90.88 - 98.53","98.54 - 99.54","99.55 - 99.99","--","--","--","100.0","No","","N"
"Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy","326","Medicare Part B Claims","Process","Y","","","8.16 - 98.66","98.67 - 99.99","--","--","--","--","--","100.0","No","","N"
"Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy","326","QCDR Measure","Process","Y","","","0.95 - 79.26","79.27 - 83.99","84.0 - 88.79","88.8 - 94.51","94.52 - 98.7","98.71 - 99.99","--","100.0","No","","N"
"""Rate of Carotid Artery Stenting (CAS) for Asymptomatic Patients, Without Major Complications (Discharged to Home by Post-Operative Day #2)""","344","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Optimal Asthma Control","398","QCDR Measure","Outcome","Y","","","0.44 - 38.94","38.95 - 49.99","50.0 - 58.04","58.05 - 80.13","80.14 - 99.99","--","--","100.0","No","","Y"
"One-Time Screening for Hepatitis C Virus (HCV) for Patients at Risk","400","QCDR Measure","Process","Y","","","0.08 - 1.34","1.35 - 2.03","2.04 - 3.77","3.78 - 8.58","8.59 - 17.68","17.69 - 27.93","27.94 - 43.6",">= 43.61","No","","N"
"Hypertension Control (Stage 1 or 2)","ACCPIN8","QCDR Measure","Intermediate Outcome","Y","","","0.08 - 19.81","19.82 - 22.56","22.57 - 25.09","25.1 - 27.53","27.54 - 28.89","28.9 - 30.61","30.62 - 34.51",">= 34.52","No","","Y"
"Disease Activity Measurement for Patients with PsA","ACR12","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Functional Status Change for Patients Post Stroke: Lower Body","FOTO2","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Screening Colonoscopy Adenoma Detection Rate","GIQIC22","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Amblyopia: Interocular visual acuity","IRIS50","QCDR Measure","Outcome","Y","","","28.78 - 42.85","42.86 - 47.61","47.62 - 53.32","53.33 - 56.51","56.52 - 57.88","57.89 - 67.56","67.57 - 68.17",">= 68.18","No","","Y"
"""Failure to Progress (FTP): Proportion of patients failing to achieve a Minimal Clinically Important Difference (MCID) in improvement in pain score, measured via the Numeric Pain Rating Scale (NPRS), in rehabilitation patients with arm, shoulder, or hand injury.""","IROMS20","QCDR Measure","Outcome","Y","","","48.04 - 46.78","46.77 - 45.23","45.22 - 44.66","44.65 - 43.07","43.06 - 41.71","41.7 - 40.71","40.7 - 39.37","<= 39.36","No","","Y"
"Use of Capnography for Non-Operating Room Anesthesia","MEDNAX53","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Prostate Cancer: Follow-Up Testing for patients on active surveillance for at least 30 months","MUSIC11","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Kidney Stones: Alpha-blockers at discharge for patients undergoing ureteroscopy or shockwave lithotripsy","MUSIC18","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Sentinel Lymph Node (SLN) Biopsies for Patients AJCC T1b-T4 Melanoma","QOPI26","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%)","1","Medicare Part B Claims","Intermediate Outcome","Y","","","34.85 - 19.28","19.27 - 14.27","14.26 - 11.12","11.11 - 8.76","8.75 - 6.95","6.94 - 5.14","5.13 - 3.62","<= 3.61","No","","Y"
"Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%)","1","eCQM","Intermediate Outcome","Y","","","93.41 - 76.9","76.89 - 59.88","59.87 - 47.42","47.41 - 37.87","37.86 - 30.74","30.73 - 25.24","25.23 - 20.01","<= 20.0","No","","Y"
"Controlling High Blood Pressure","236","eCQM","Intermediate Outcome","Y","","","0.04 - 51.91","51.92 - 57.47","57.48 - 61.83","61.84 - 65.48","65.49 - 69.16","69.17 - 72.95","72.96 - 77.74",">= 77.75","No","","Y"
"Controlling High Blood Pressure","236","Medicare Part B Claims","Intermediate Outcome","Y","","","0.61 - 62.26","62.27 - 68.42","68.43 - 73.57","73.58 - 77.9","77.91 - 81.98","81.99 - 87.49","87.5 - 92.49",">= 92.5","No","","Y"
"Unplanned Reoperation within the 30 Day Postoperative Period","355","QCDR Measure","Outcome","Y","","","5.33 - 2.65","2.64 - 1.34","1.33 - 0.73","0.72 - 0.01","--","--","--","0.0","No","","Y"
"Adherence to Antipsychotic Medications For Individuals with Schizophrenia","383","QCDR Measure","Intermediate Outcome","Y","","","0.75 - 69.32","69.33 - 85.64","85.65 - 96.89","96.9 - 99.99","--","--","--","100.0","No","","Y"
"Rate of Surgical Conversion from Lower Extremity Endovascular Revascularization Procedure","437","QCDR Measure","Outcome","Y","","","1.98 - 0.82","0.81 - 0.48","0.47 - 0.01","--","--","--","--","0.0","No","","Y"
"Rate of Surgical Conversion from Lower Extremity Endovascular Revascularization Procedure","437","Medicare Part B Claims","Outcome","Y","","","1.67 - 0.01","--","--","--","--","--","--","0.0","No","","Y"
"Statin Therapy for the Prevention and Treatment of Cardiovascular Disease","438","eCQM","Process","Y","","","0.42 - 62.89","62.9 - 66.66","66.67 - 69.22","69.23 - 71.73","71.74 - 74.06","74.07 - 76.59","76.6 - 80.14",">= 80.15","No","","N"
"Appropriate Workup Prior to Endometrial Ablation","448","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Chronic Skin Conditions: Patient Reported Quality-of-Life","AAD8","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Patient reported falls and plan of care","AAN34","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Report Turnaround Time: CT","ACRAD18","QCDR Measure","Outcome","Y","","","10.66 - 6.53","6.52 - 5.0","4.99 - 4.2","4.19 - 3.51","3.5 - 2.77","2.76 - 2.35","2.34 - 1.71","<= 1.7","No","","Y"
"Use of Neuraxial Techniques and/or Peripheral Nerve Blocks for Total Knee Arthroplasty (TKA)","AQI56","QCDR Measure","Process","Y","","","10.18 - 87.32","87.33 - 91.98","91.99 - 96.11","96.12 - 97.37","97.38 - 98.88","98.89 - 99.5","99.51 - 99.99","100.0","No","","N"
"Avoidance of Long-Acting (LA) or Extended-Release (ER) Opiate Prescriptions and Opiate Prescriptions for Greater Than 3 Days Duration for Acute Pain","ECPR55","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Functional Status Change for Patients With Neck Functional Status Deficit","HM5","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"""Failure to Progress (FTP): Proportion of patients not achieving a Minimal Clinically Important Difference (MCID) to indicate functional improvement in rehabilitation of patients with hip, leg or ankle injuries using the validated Lower Extremity Function Scale (LEFS) score, or equivalent instrument which has undergone peer reviewed published validation and demonstrates a peer reviewed published MCID.""","IROMS13","QCDR Measure","Outcome","Y","","","41.18 - 39.4","39.39 - 37.89","37.88 - 36.87","36.86 - 34.88","34.87 - 33.65","33.64 - 32.82","32.81 - 31.22","<= 31.21","No","","Y"
"CHANGE IN PATIENT REPORTED QUALITY OF LIFE FOLLOWING EPIDURAL CORTICOSTEROID INJECTION","NIPM22","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Appropriate non-invasive arterial testing for patients with intermittent claudication who are undergoing a LE peripheral vascular intervention","OEIS6","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Oncology: Patient-reported pain improvement","PIMSH4","QCDR Measure","Outcome","Y","","","10.2 - 30.28","30.29 - 35.62","35.63 - 38.18","38.19 - 40.8","40.81 - 44.43","44.44 - 47.61","47.62 - 51.26",">= 51.27","No","","Y"
"Bunion Outcome - Adult and Adolescent","REGCLR3","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Patient satisfaction following spinal fusion surgery","SPINETRACK8","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Perioperative Care: Selection of Prophylactic Antibiotic – First OR Second-Generation Cephalosporin","21","QCDR Measure","Process","Y","","","0.16 - 72.42","72.43 - 96.11","96.12 - 99.99","--","--","--","--","100.0","No","","Y"
"Perioperative Care: Selection of Prophylactic Antibiotic – First OR Second-Generation Cephalosporin","21","Medicare Part B Claims","Process","Y","","","0.96 - 99.99","--","--","--","--","--","--","100.0","No","","Y"
"Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow","67","QCDR Measure","Process","Y","","","9.68 - 96.4","96.41 - 99.99","--","--","--","--","--","100.0","No","","N"
"Pneumococcal Vaccination Status for Older Adults","111","eCQM","Process","Y","","","0.01 - 23.82","23.83 - 38.43","38.44 - 50.05","50.06 - 59.82","59.83 - 67.58","67.59 - 74.63","74.65 - 81.34",">= 81.35","No","","N"
"Pneumococcal Vaccination Status for Older Adults","111","Medicare Part B Claims","Process","Y","","","0.21 - 68.67","68.68 - 76.25","76.26 - 82.48","82.49 - 87.36","87.37 - 92.65","92.66 - 97.7","97.71 - 99.99","100.0","No","","N"
"Parkinson’s Disease: Cognitive Impairment or Dysfunction Assessment for Patients with Parkinson's Disease","291","QCDR Measure","Process","Y","","","1.79 - 21.51","21.52 - 57.77","57.78 - 88.75","88.76 - 97.29","97.3 - 99.99","--","--","100.0","No","","N"
"Adult Sinusitis: Appropriate Choice of Antibiotic: Amoxicillin With or Without Clavulanate Prescribed for Patients with Acute Bacterial Sinusitis (Appropriate Use)","332","QCDR Measure","Process","Y","","","18.88 - 52.89","52.9 - 61.72","61.73 - 75.92","75.93 - 86.37","86.38 - 89.88","89.89 - 95.99","96.0 - 99.99","100.0","No","","Y"
"Adult Sinusitis: Computerized Tomography (CT) for Acute Sinusitis (Overuse)","333","QCDR Measure","Efficiency and Cost/Resource Use","Y","","","6.84 - 2.23","2.22 - 0.96","0.95 - 0.21","0.2 - 0.01","--","--","--","0.0","No","","Y"
"Children Who Have Dental Decay or Cavities","378","eCQM","Outcome","Y","","","1.72 - 0.92","0.91 - 0.43","0.42 - 0.01","--","--","--","--","0.0","No","","Y"
"Non-Recommended Cervical Cancer Screening in Adolescent Females","443","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"HIV Screening","475","eCQM","Process","Y","","","0.12 - 0.96","0.97 - 2.44","2.45 - 3.22","3.23 - 7.8","7.81 - 15.54","15.55 - 99.99","--","100.0","No","","N"
"Activity counseling for back pain","AAN26","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Comprehensive Epilepsy Care Center Referral or Discussion for Patients with Epilepsy","AAN29","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Hypotension Prevention After Spinal Placement for Elective Cesarean Section","ABG40","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Peripheral Artery Disease: Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk","ACCPIN7","QCDR Measure","Process","Y","","","32.83 - 72.53","72.54 - 75.81","75.82 - 79.85","79.86 - 82.34","82.35 - 83.69","83.7 - 86.66","86.67 - 89.33",">= 89.34","No","","N"
"COPD Exacerbation or CHF Exacerbation requiring Hospital Admission: Palliative Care Evaluation","ACQR16","QCDR Measure","Efficiency and Cost/Resource Use","Y","","","33.33 - 66.66","66.67 - 70.58","70.59 - 73.27","73.28 - 75.97","75.98 - 80.55","80.56 - 83.92","83.93 - 87.58",">= 87.59","No","","Y"
"Avoidance of Opioid Prescriptions for Closure and Reconstruction After Skin Cancer Resection","ASPS29","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Helicobacter pylori Status and Turnaround Time","CAP28","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Venous Thromboembolism (VTE) Prophylaxis","HCPR14","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Myocardial Perfusion Imaging (MPI) studies - Radiation Reduction Strategies","IGR17","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Kidney Stones: Post-ureteroscopy and shockwave lithotripsy imaging for any stones","MUSIC24","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"CHANGE IN PATIENT REPORTED QUALITY OF LIFE AND FUNCTIONAL STATUS FOLLOWING MEDIAL BRANCH RADIOFREQUENCY ABLATION","NIPM19","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Notification to the ordering provider requesting thyroid screening tests other than only a Thyroid Stimulating Hormone (TSH) test in the initial screening of a patient with a suspected thyroid disorder","NPQR2","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Use of Breast Cancer Risk Score on Mammography","QMM18","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Upper Extremity Edema Improvement","RCOIR10","QCDR Measure","Outcome","Y","","","52.41 - 67.08","67.09 - 70.44","70.45 - 74.08","74.09 - 75.89","75.9 - 76.96","76.97 - 78.56","78.57 - 84.12",">= 84.13","No","","Y"
"Unplanned Hospital Readmission within 30 Days of Principal Procedure","356","QCDR Measure","Outcome","Y","","","9.43 - 6.83","6.82 - 4.45","4.44 - 3.55","3.54 - 1.9","1.89 - 0.69","0.68 - 0.01","--","0.0","No","","Y"
"Back Pain After Lumbar Discectomy/Laminectomy","459","","patientReportedOutcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Skin Cancer: Biopsy Reporting Time - Clinician to Patient","AAD6","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Fatigue Screening and Follow-Up for Patients with MS","AAN33","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Exercise and Appropriate Physical Activity Counseling for Patients with MS","AAN8","QCDR Measure","Process","Y","","","2.65 - 58.81","58.82 - 69.99","70.0 - 73.99","74.0 - 80.76","80.77 - 89.67","89.68 - 92.49","92.5 - 96.14",">= 96.15","No","","N"
"Prevention of Arterial Line-Related Bloodstream Infections","AQI70","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Ambulatory Glucose Management","AQI71","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Initiation of the Initial Sepsis Bundle","ECPR40","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Unintentional Weight Loss – Risk Assessment and Plan of Care","HCPR18","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Renal Mass: ED Visit or Readmission within 30 days of partial nephrectomy","MUSIC26","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Anti-Depressant Medication Management","9","eCQM","Process","Y","","","2.38 - 65.29","65.3 - 70.74","70.75 - 74.4","74.41 - 78.14","78.15 - 80.96","80.97 - 83.76","83.77 - 86.6",">= 86.61","No","","N"
"Colorectal Cancer Screening","113","Medicare Part B Claims","Process","Y","","","0.35 - 63.18","63.19 - 76.16","76.17 - 84.99","85.0 - 92.01","92.02 - 96.76","96.77 - 99.41","99.42 - 99.99","100.0","No","","N"
"Colorectal Cancer Screening","113","eCQM","Process","Y","","","0.0 - 15.13","15.14 - 27.98","27.99 - 39.31","39.32 - 49.98","49.99 - 59.41","59.42 - 68.66","68.67 - 76.96",">= 76.97","No","","N"
"Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%)","118","QCDR Measure","Process","Y","","","6.67 - 72.84","72.85 - 76.72","76.73 - 79.99","80.0 - 82.1","82.11 - 85.11","85.12 - 86.9","86.91 - 90.49",">= 90.5","No","","N"
"Stroke and Stroke Rehabilitation: Thrombolytic Therapy","187","QCDR Measure","Process","Y","","","8.74 - 83.01","83.02 - 88.31","88.32 - 91.81","91.82 - 93.54","93.55 - 95.44","95.45 - 97.36","97.37 - 99.99","100.0","No","","N"
"Childhood Immunization Status","240","eCQM","Process","Y","","","0.52 - 17.9","17.91 - 25.28","25.29 - 32.24","32.25 - 36.35","36.36 - 40.16","40.17 - 44.69","44.7 - 49.55",">= 49.56","No","","N"
"Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy","268","QCDR Measure","Process","Y","","","0.18 - 19.63","19.64 - 35.92","35.93 - 40.34","40.35 - 54.02","54.03 - 69.47","69.48 - 89.49","89.5 - 94.99",">= 95.0","No","","N"
"Maternity Care: Postpartum Follow-up and Care Coordination","336","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Total Knee Replacement: Shared Decision-Making: Trial of Conservative (Non-surgical) Therapy","350","QCDR Measure","Process","Y","","","2.22 - 99.59","99.6 - 99.99","--","--","--","--","--","100.0","No","","Y"
"Follow-Up Care for Children Prescribed ADHD Medication (ADD)","366","eCQM","Process","Y","","","1.19 - 19.99","20.0 - 24.13","24.14 - 29.02","29.03 - 35.9","35.91 - 39.52","39.53 - 45.01","45.02 - 49.99",">= 50.0","No","","N"
"Appropriate Follow-up Imaging for Incidental Thyroid Nodules in Patients","406","Medicare Part B Claims","Process","Y","","","5.0 - 1.19","1.18 - 0.01","--","--","--","--","--","0.0","No","","Y"
"Appropriate Follow-up Imaging for Incidental Thyroid Nodules in Patients","406","QCDR Measure","Process","Y","","","11.39 - 2.28","2.27 - 0.01","--","--","--","--","--","0.0","No","","Y"
"Evaluation or Interview for Risk of Opioid Misuse","414","QCDR Measure","Process","Y","","","0.12 - 92.2","92.21 - 99.37","99.38 - 99.99","--","--","--","--","100.0","No","","Y"
"Varicose Vein Treatment with Saphenous Ablation: Outcome Survey","420","","patientReportedOutcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Prevention of Post-Operative Nausea and Vomiting (PONV) – Combination Therapy","430","QCDR Measure","Process","Y","","","1.36 - 96.67","96.68 - 98.13","98.14 - 98.89","98.9 - 99.47","99.48 - 99.76","99.77 - 99.92","99.93 - 99.99","100.0","No","","Y"
"Uterine Artery Embolization Technique: Documentation of Angiographic Endpoints and Interrogation of Ovarian Arteries","465","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"ABCDEF Bundle - Early mobility for ICU patients","ACQR12","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Report Turnaround Time: Mammography","ACRAD25","QCDR Measure","Outcome","Y","","","53.67 - 29.78","29.77 - 24.09","24.08 - 18.7","18.69 - 13.76","13.75 - 9.63","9.62 - 5.93","5.92 - 3.07","<= 3.06","No","","Y"
"Functional Status Change for Patients With Lower Extremity Functional Status Deficit","HM8","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Labor Epidural Failure when Converting from Labor Analgesia to Cesarean Section Anesthesia","MEDNAX54","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
